Trazodone - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (7)Enzymes (4)Carriers (1)Transporters (1)

Targets (7)Enzymes (4)Carriers (1)Transporters (1)Biointeractions (12)

Identification

Name

Trazodone

Accession Number

DB00656 (APRD00533)

Type

Small Molecule

Groups

Approved, Investigational

Description

A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

2-(3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl)[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one

Trazodona

Trazodone

Trazodonum

External IDs

J10.767K

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Trazodone Hydrochloride	6E8ZO8LRNM	25332-39-2	OHHDIOKRWWOXMT-UHFFFAOYSA-N	Details

Product Images

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Desyrel Dividose Tab 300mg	Tablet	300 mg	Oral	Bristol Labs Division Of Bristol Myers Squibb	1989-12-31	1999-08-09	Canada
Desyrel Dividose Tablet 150 mg	Tablet	150 mg	Oral	Bristol Myers Squibb	1988-12-31	2010-01-05	Canada
Desyrel Tab 100mg	Tablet	100 mg	Oral	Bristol Myers Squibb	1983-12-31	2010-09-07	Canada
Desyrel Tab 50mg	Tablet	50 mg	Oral	Bristol Myers Squibb	1983-12-31	2010-05-14	Canada
Dom-trazodone Tablets - 50mg	Tablet	50 mg	Oral	Dominion Pharmacal	1996-12-31	Not applicable	Canada
Dom-trazodone Tablets-100mg	Tablet	100 mg	Oral	Dominion Pharmacal	1996-12-31	Not applicable	Canada
Mar-trazodone	Tablet	50 mg	Oral	Marcan Pharmaceuticals Inc	Not applicable	Not applicable	Canada
Mar-trazodone	Tablet	100 mg	Oral	Marcan Pharmaceuticals Inc	Not applicable	Not applicable	Canada
Mar-trazodone	Tablet	150 mg	Oral	Marcan Pharmaceuticals Inc	Not applicable	Not applicable	Canada
Mylan-trazodone	Tablet	100 mg	Oral	Mylan Pharmaceuticals	1997-09-05	2016-06-28	Canada
Mylan-trazodone	Tablet	50 mg	Oral	Mylan Pharmaceuticals	1997-09-05	2016-06-28	Canada
Mylan-trazodone	Tablet	150 mg	Oral	Mylan Pharmaceuticals	1997-11-28	2016-06-28	Canada
Ntp-trazodone	Tablet	100 mg	Oral	Teva	Not applicable	Not applicable	Canada
Ntp-trazodone	Tablet	150 mg	Oral	Teva	Not applicable	Not applicable	Canada
Ntp-trazodone	Tablet	50 mg	Oral	Teva	Not applicable	Not applicable	Canada
Nu-trazodone - Tab 100mg	Tablet	100 mg	Oral	Nu Pharm Inc	1995-12-31	2012-09-04	Canada
Nu-trazodone - Tab 50mg	Tablet	50 mg	Oral	Nu Pharm Inc	1995-12-31	2012-09-04	Canada
Nu-trazodone-D - Tab 150mg	Tablet	150 mg	Oral	Nu Pharm Inc	1995-12-31	2012-09-04	Canada
Oleptro	Tablet, extended release	150 mg/1	Oral	Angelini Pharma Inc.	2010-02-02	2016-03-29	US
Oleptro	Tablet, extended release	150 mg	Oral	Angelini Pharma Inc.	2011-03-09	Not applicable	Canada
Oleptro	Tablet, extended release	300 mg/1	Oral	Angelini Pharma Inc.	2010-02-02	2016-03-29	US
Oleptro	Tablet, extended release	300 mg	Oral	Angelini Pharma Inc.	2011-03-09	Not applicable	Canada
Penta-trazodone Tablets	Tablet	100 mg	Oral	Pentapharm Ltd.	Not applicable	Not applicable	Canada
Penta-trazodone Tablets	Tablet	150 mg	Oral	Pentapharm Ltd.	Not applicable	Not applicable	Canada
Penta-trazodone Tablets	Tablet	50 mg	Oral	Pentapharm Ltd.	Not applicable	Not applicable	Canada
PHL-trazodone	Tablet	50 mg	Oral	Pharmel Inc	1998-02-17	Not applicable	Canada
PHL-trazodone	Tablet	100 mg	Oral	Pharmel Inc	1998-02-17	Not applicable	Canada
PMS Trazodone HCl Tab 100mg	Tablet	100 mg	Oral	Pharmascience Inc	1993-12-31	Not applicable	Canada
PMS Trazodone HCl Tab 50mg	Tablet	50 mg	Oral	Pharmascience Inc	1993-12-31	Not applicable	Canada
PMS-trazodone	Tablet	75 mg	Oral	Pharmascience Inc	1998-02-17	Not applicable	Canada
Ratio-trazodone	Tablet	100 mg	Oral	Teva	2006-03-10	Not applicable	Canada
Ratio-trazodone	Tablet	150 mg	Oral	Teva	2006-03-10	Not applicable	Canada
Ratio-trazodone	Tablet	50 mg	Oral	Teva	2006-03-10	Not applicable	Canada
Ratio-trazodone Tab 150mg	Tablet	150 mg	Oral	Ratiopharm Inc Division Of Teva Canada Limited	1994-12-31	2009-01-22	Canada
Ratio-trazodone Tablets 100mg	Tablet	100 mg	Oral	Ratiopharm Inc Division Of Teva Canada Limited	1994-12-31	2009-01-22	Canada
Ratio-trazodone Tablets 50mg	Tablet	50 mg	Oral	Ratiopharm Inc Division Of Teva Canada Limited	1994-12-31	2009-01-22	Canada
Scheinpharm Trazodone	Tablet	50 mg	Oral	Schein Pharmaceutical Canada Inc.	2000-09-13	2004-07-26	Canada
Scheinpharm Trazodone	Tablet	100 mg	Oral	Schein Pharmaceutical Canada Inc.	2000-09-13	2004-07-26	Canada
Teva-trazodone	Tablet	150 mg	Oral	Teva	1995-12-31	Not applicable	Canada
Teva-trazodone	Tablet	100 mg	Oral	Teva	1995-12-31	Not applicable	Canada
Teva-trazodone	Tablet	50 mg	Oral	Teva	1995-12-31	Not applicable	Canada
Trazodone	Tablet	100 mg	Oral	Sanis Health Inc	2010-04-30	Not applicable	Canada
Trazodone	Tablet	150 mg	Oral	Sanis Health Inc	2010-04-30	Not applicable	Canada
Trazodone	Tablet	50 mg	Oral	Sanis Health Inc	2010-04-30	Not applicable	Canada
Trazodone - 100 - Tab 100mg	Tablet	100 mg	Oral	Pro Doc Limitee	1996-12-31	Not applicable	Canada
Trazodone-150 D - Tab 150mg	Tablet	150 mg	Oral	Pro Doc Limitee	1996-12-31	Not applicable	Canada
Trazodone-50 - Tab 50mg	Tablet	50 mg	Oral	Pro Doc Limitee	1996-12-31	Not applicable	Canada
Trazorel	Tablet	100 mg	Oral	Valeant Canada Lp Valeant Canada S.E.C.	1997-03-07	2014-07-30	Canada
Trazorel	Tablet	150 mg	Oral	Valeant Canada Lp Valeant Canada S.E.C.	1997-02-04	2014-07-30	Canada
Trazorel	Tablet	50 mg	Oral	Valeant Canada Lp Valeant Canada S.E.C.	1997-02-04	2014-07-30	Canada
Zym-trazodone	Tablet	100 mg	Oral	Zymcan Pharmaceuticals Inc	2009-06-23	2014-06-16	Canada
Zym-trazodone	Tablet	68.25 mg	Oral	Zymcan Pharmaceuticals Inc	2004-04-06	2014-06-16	Canada
Zym-trazodone	Tablet	50 mg	Oral	Zymcan Pharmaceuticals Inc	2009-06-23	2014-06-16	Canada

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo-trazodone D Tablets 150mg	Tablet	150 mg	Oral	Apotex Corporation	1995-12-31	Not applicable	Canada
Apo-trazodone Tablets 100mg	Tablet	100 mg	Oral	Apotex Corporation	1995-12-31	Not applicable	Canada
Apo-trazodone Tablets 50mg	Tablet	50 mg	Oral	Apotex Corporation	1995-12-31	Not applicable	Canada
Trazodone	Tablet	50 mg/1	Oral	Northwind Pharmaceuticals	2014-12-01	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Clinical Solutions Wholsesale	1990-09-30	2017-07-01	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Carilion Materials Management	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Rebel Distributors	1988-03-09	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Teva	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet, film coated	100 mg/1	Oral	A S Medication Solutions	2010-05-30	2017-06-20	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Cardinal Health	2008-11-17	Not applicable	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Directrx	2014-01-01	Not applicable	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Apotex Corporation	2008-11-17	Not applicable	US
Trazodone Hydrochloride	Tablet, film coated	50 mg/1	Oral	Apotheca, Inc.	2010-05-30	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2011-12-14	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Remedy Repack	2017-06-07	Not applicable	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Aidarex Pharmaceuticals LLC	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Dispensing Solutions, Inc.	2011-01-20	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	TYA Pharmaceuticals	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Kaiser Foundations Hospitals	1987-12-22	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	TYA Pharmaceuticals	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Remedy Repack	2016-11-17	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Legacy Pharmaceutical Packaging	2008-11-17	2017-03-04	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Torrent Pharmaceuticals Limited	2013-11-27	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Unit Dose Services	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet, film coated	50 mg/1	Oral	Proficient Rx LP	2010-05-30	Not applicable	US
Trazodone Hydrochloride	Tablet, film coated	50 mg/1	Oral	bryant ranch prepack	2010-05-30	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2012-02-28	Not applicable	US
Trazodone Hydrochloride	Tablet, film coated	100 mg/1	Oral	A S Medication Solutions	2010-05-30	2017-06-20	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Cardinal Health	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Blenheim Pharmacal, Inc.	2010-03-03	Not applicable	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Amerincan Health Packaging	2012-09-03	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Proficient Rx LP	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet, film coated	100 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2010-05-30	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Cardinal Health	2011-01-20	2016-03-11	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Nucare Pharmaceuticals, Inc.	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2011-01-20	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Dispensing Solutions, Inc.	2011-01-20	Not applicable	US
Trazodone Hydrochloride	Tablet, film coated	100 mg/1	Oral	Remedy Repack	2017-01-19	Not applicable	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Avera Mc Kennan Hospital	2015-04-17	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	STAT RX LLC USA	1987-12-11	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2011-12-14	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Av Kare, Inc.	2014-02-06	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	bryant ranch prepack	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Remedy Repack	2006-11-15	Not applicable	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Physicians Total Care, Inc.	1992-02-20	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Torrent Pharmaceuticals Limited	2013-11-27	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Legacy Pharmaceutical Packaging	2008-11-17	2017-03-04	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Golden State Medical Supply	2008-11-17	Not applicable	US
Trazodone Hydrochloride	Tablet, film coated	150 mg/1	Oral	A S Medication Solutions	1993-03-24	2017-06-20	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Aidarex Pharmaceuticals LLC	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet, film coated	50 mg/1	Oral	Remedy Repack	2015-11-06	Not applicable	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Av Pak	2016-08-08	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Clinical Solutions Wholsesale	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	A S Medication Solutions	2008-11-17	2017-06-20	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	bryant ranch prepack	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	bryant ranch prepack	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet, film coated	100 mg/1	Oral	Sun Pharmaceutical Industries Limited	1993-03-24	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Apotex Corporation	2008-11-17	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Remedy Repack	2016-10-07	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Directrx	2014-01-01	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	A S Medication Solutions	2008-11-17	2017-06-20	US
Trazodone Hydrochloride	Tablet, film coated	100 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2010-05-30	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Cardinal Health	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Major	2004-02-03	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Contract Pharmacy Services Pa	2010-03-09	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Rebel Distributors	1987-12-11	Not applicable	US
Trazodone Hydrochloride	Tablet	300 mg/1	Oral	Av Kare, Inc.	2014-02-06	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2014-02-06	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Physicians Total Care, Inc.	1996-04-09	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Cardinal Health	2008-11-17	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Blenheim Pharmacal, Inc.	2011-04-01	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Keltman Pharmaceuticals Inc.	2010-11-17	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Clinical Solutions Wholsesale	1990-09-30	2017-07-01	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Major	2008-11-17	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Remedy Repack	2013-03-27	2016-11-01	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Teva	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	A S Medication Solutions	1990-09-30	2017-06-20	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Cardinal Health	2008-11-17	Not applicable	US
Trazodone Hydrochloride	Tablet, film coated	150 mg/1	Oral	A S Medication Solutions	1993-03-24	2017-06-20	US
Trazodone Hydrochloride	Tablet	300 mg/1	Oral	Apotex Corporation	2009-01-05	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	A S Medication Solutions	1990-09-30	2017-06-20	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2008-11-17	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Stat Rx USA	2008-11-17	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Cardinal Health	2004-02-03	Not applicable	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2016-06-15	Not applicable	US
Trazodone Hydrochloride	Tablet, film coated	50 mg/1	Oral	Qualitest	2010-05-30	Not applicable	US
Trazodone Hydrochloride	Tablet, film coated	50 mg/1	Oral	Med Vantx, Inc.	1993-03-24	Not applicable	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Remedy Repack	2016-11-17	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Mc Kesson Contract Packaging	2011-10-11	Not applicable	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Torrent Pharmaceuticals Limited	2013-11-27	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Nucare Pharmaceuticals, Inc.	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet	300 mg/1	Oral	Teva	1999-05-03	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	bryant ranch prepack	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2012-02-28	Not applicable	US
Trazodone Hydrochloride	Tablet, film coated	50 mg/1	Oral	Amerincan Health Packaging	2013-12-01	2017-11-30	US
Trazodone Hydrochloride	Tablet, film coated	150 mg/1	Oral	Sun Pharmaceutical Industries Limited	1993-03-24	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Unit Dose Services	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Remedy Repack	2010-09-28	2016-10-13	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Cardinal Health	2011-01-20	2016-03-11	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2011-01-20	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Contract Pharmacy Services Pa	2010-08-11	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	STAT RX LLC USA	1987-12-11	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Av Kare, Inc.	2014-02-06	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Remedy Repack	2007-07-06	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Golden State Medical Supply	2008-11-17	Not applicable	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Clinical Solutions Wholsesale	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	A S Medication Solutions	2008-11-17	2017-06-20	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Apotex Corporation	2008-11-17	Not applicable	US
Trazodone Hydrochloride	Tablet, film coated	100 mg/1	Oral	Proficient Rx LP	2010-05-30	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Directrx	2014-01-01	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	A S Medication Solutions	2008-11-17	2017-06-20	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	St. Marys Medical Park Pharmacy	2016-06-14	Not applicable	US
Trazodone Hydrochloride	Tablet, film coated	50 mg/1	Oral	A S Medication Solutions	2010-05-30	2017-06-20	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Cardinal Health	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Blenheim Pharmacal, Inc.	2012-01-18	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Contract Pharmacy Services Pa	2010-08-11	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Carilion Materials Management	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Rebel Distributors	1987-12-11	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Teva	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet, film coated	50 mg/1	Oral	A S Medication Solutions	2010-05-30	2017-06-20	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Aidarex Pharmaceuticals LLC	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Mc Kesson Contract Packaging	2012-01-25	Not applicable	US
Trazodone Hydrochloride	Tablet	300 mg/1	Oral	Torrent Pharmaceuticals Limited	2013-11-27	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2008-11-17	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Remedy Repack	2008-01-29	2016-12-30	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	bryant ranch prepack	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet, film coated	100 mg/1	Oral	Remedy Repack	2016-01-07	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Physicians Total Care, Inc.	1997-05-08	Not applicable	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Blenheim Pharmacal, Inc.	2014-05-22	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Keltman Pharmaceuticals Inc.	2010-11-17	Not applicable	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Clinical Solutions Wholsesale	1990-09-30	2017-07-01	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Major	2008-11-17	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Aidarex Pharmaceuticals LLC	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	A S Medication Solutions	1990-09-30	2017-06-20	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Clinical Solutions Wholsesale	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	A S Medication Solutions	2008-11-17	2017-06-20	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Apotex Corporation	2014-12-31	Not applicable	US
Trazodone Hydrochloride	Tablet, film coated	100 mg/1	Oral	A S Medication Solutions	1993-03-24	2017-06-20	US
Trazodone Hydrochloride	Tablet, film coated	50 mg/1	Oral	Sun Pharmaceutical Industries Limited	1993-03-24	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Proficient Rx LP	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet, film coated	50 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2010-05-30	Not applicable	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Cardinal Health	2004-02-03	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Avera Mc Kennan Hospital	2015-03-02	Not applicable	US
Trazodone Hydrochloride	Tablet, film coated	100 mg/1	Oral	Qualitest	2010-05-30	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Med Vantx, Inc.	2011-01-20	Not applicable	US
Trazodone Hydrochloride	Tablet, film coated	50 mg/1	Oral	Remedy Repack	2016-08-31	Not applicable	US
Trazodone Hydrochloride	Tablet, film coated	50 mg/1	Oral	A S Medication Solutions	1993-03-24	2017-06-20	US
Trazodone Hydrochloride	Tablet, film coated	100 mg/1	Oral	Amerincan Health Packaging	2013-12-01	2017-10-31	US
Trazodone Hydrochloride	Tablet	100 mg/1	Oral	Avera Mc Kennan Hospital	2016-06-24	Not applicable	US
Trazodone Hydrochloride	Tablet	300 mg/1	Oral	bryant ranch prepack	1999-05-03	Not applicable	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Remedy Repack	2010-10-26	2016-10-13	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Cardinal Health	1990-09-30	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Major	2004-02-03	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Contract Pharmacy Services Pa	2010-03-09	Not applicable	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	STAT RX LLC USA	1988-03-09	Not applicable	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Av Kare, Inc.	2014-02-06	Not applicable	US
Trazodone Hydrochloride	Tablet	50 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2014-02-06	Not applicable	US
Trazodone Hydrochloride	Tablet	150 mg/1	Oral	Golden State Medical Supply	2008-11-17	Not applicable	US

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Beneficat	Not Available
Deprax	Not Available
Desirel	Not Available
Desyrel	Bristol-Myers Squibb
Desyrel Dividose	Bristol-Myers Squibb
Mesyrel	Not Available
Molipaxin	Not Available
Thombran	Not Available
Trialodine	Not Available
Trittico	Not Available

Brand mixtures

Name	Labeller	Ingredients
Trazamine	Physician Therapeutics Llc	Choline Trazodone

Categories

UNII

YBK48BXK30

CAS number

19794-93-5

Weight

Average: 371.864
Monoisotopic: 371.151288058

Chemical Formula

C₁₉H₂₂ClN₅O

InChI Key

PHLBKPHSAVXXEF-UHFFFAOYSA-N

InChI

InChI=1S/C19H22ClN5O/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25/h1-3,5-7,9,15H,4,8,10-14H2

IUPAC Name

2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-2H,3H-[1,2,4]triazolo[4,3-a]pyridin-3-one

SMILES

ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1

Pharmacology

Indication

For the treatment of depression.

Structured Indications

Pharmacodynamics

Trazodone is an antidepressant and hypnotic chemically unrelated to tricyclic, tetracyclic, or other known antidepressant agents. The mechanism of trazodone's antidepressant action in man is not fully understood. In animals, trazodone selectively inhibits serotonin uptake by brain synaptosomes and potentiates the behavioral changes induced by the serotonin precursor, 5-hydroxytryptophan. Cardiac conduction effects of trazodone in the anesthetized dog are qualitatively dissimilar and quantitatively less pronounced than those seen with tricyclic antidepressants. Trazodone is not a monoamine oxidase inhibitor and, unlike amphetamine-type drugs, does not stimulate the central nervous system. In man, trazodone is well absorbed after oral administration without selective localization in any tissue. Since the clearance of trazodone from the body is sufficiently variable, in some patients trazodone may accumulate in the plasma.

Mechanism of action

Trazodone binds at 5-HT2 receptor, it acts as a serotonin agonist at high doses and a serotonin antagonist at low doses. Like fluoxetine, trazodone's antidepressant activity likely results from blockage of serotonin reuptake by inhibiting serotonin reuptake pump at the presynaptic neuronal membrane. If used for long time periods, postsynaptic neuronal receptor binding sites may also be affected. The sedative effect of trazodone is likely the result of alpha-adrenergic blocking action and modest histamine blockade at H1 receptor. It weakly blocks presynaptic alpha2-adrenergic receptors and strongly inhibits postsynaptic alpha1 receptors. Trazodone does not affect the reuptake of norepinephrine or dopamine within the CNS.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
5-hydroxytryptamine receptor 2A	Protein	yes	antagonist	Human	P28223	details
5-hydroxytryptamine receptor 2C	Protein	yes	agonist	Human	P28335	details
Sodium-dependent serotonin transporter	Protein	yes	inhibitor	Human	P31645	details
5-hydroxytryptamine receptor 1A	Protein	yes	partial agonist	Human	P08908	details
Histamine H1 receptor	Protein	unknown	antagonist	Human	P35367	details
Alpha-1A adrenergic receptor	Protein	no	antagonist	Human	P35348	details
Alpha-2A adrenergic receptor	Protein	no	antagonist	Human	P08913	details

Absorption

Rapidly and almost completely absorbed following oral administration. Food may decrease the rate and extent of absorption.

Volume of distribution

Not Available

Protein binding

89-95% bound to plasma proteins in vitro

Metabolism

Undergoes extensive hepatic metabolism via hydroxylation, N-dealkylation, N-oxidation and splitting of the pyridine ring. Cytochrome P450 (CYP) 3A4 catalyzes the formation of the major active metabolite, m-chlorophenylpiperazine (m-CPP). Metabolites may be further conjugated to glucuonic acid or glutathione. CYP2D6 is responsible for 4'-hydroxylation of m-CPP and the formation of at least one glutathione conjugates of m-CPP, a quinone imine-sulhydryl adduct. Oxotriazolopyridinpropionic acid, an inactive metabolite, and its conjugates account for about 20% of the total excreted oral dose. Less than 1% of the oral dose is excreted unchanged. Approximately 70-75% of the dose is eliminated in urine with the remainder being excreted in feces via biliary elimination.

Substrate	Enzymes	Product
Trazodone	Cytochrome P450 2D6 Cytochrome P450 3A4 Cytochrome P450 3A5	4'-hydroxytrazodone glutathione	Details
Trazodone	Cytochrome P450 3A4	m-chlorophenylpiperazine (m-CPP)	Details
Trazodone	Cytochrome P450 3A4	triazolopropionic acid	Details
Trazodone	Cytochrome P450 3A4	triazolopyridinone epoxide	Details
Trazodone	Cytochrome P450 3A4	4'-hydroxytrazodone	Details
Trazodone	Not Available	Glutathione	Details
Trazodone	Not Available	Glucuonic acid	Details
Trazodone	Not Available	Oxotriazolopyridinpropionic acid	Details

Route of elimination

Not Available

Half life

Undergoes biphasic elimination with an initial phase t_{1/2 α} of 3-6 hours and a terminal phase t_{1/2 β} of 5-9 hours.

Clearance

Not Available

Toxicity

LD₅₀=96mg/kg (i.v. in mice)

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
7-Nitroindazole	The risk or severity of adverse effects can be increased when Trazodone is combined with 7-Nitroindazole.	Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	The risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Trazodone.	Experimental
Abiraterone	The serum concentration of Trazodone can be increased when it is combined with Abiraterone.	Approved
Acebutolol	The serum concentration of Acebutolol can be decreased when it is combined with Trazodone.	Approved
Acepromazine	The risk or severity of adverse effects can be increased when Acepromazine is combined with Trazodone.	Approved, Vet Approved
Aceprometazine	The risk or severity of adverse effects can be increased when Trazodone is combined with Aceprometazine.	Approved
Acetaminophen	The serum concentration of Acetaminophen can be decreased when it is combined with Trazodone.	Approved
Acetophenazine	The risk or severity of adverse effects can be increased when Trazodone is combined with Acetophenazine.	Approved
Acetylsalicylic acid	The serum concentration of Acetylsalicylic acid can be decreased when it is combined with Trazodone.	Approved, Vet Approved
Adipiplon	The risk or severity of adverse effects can be increased when Trazodone is combined with adipiplon.	Investigational
Afatinib	The serum concentration of Afatinib can be decreased when it is combined with Trazodone.	Approved
Agomelatine	The risk or severity of adverse effects can be increased when Trazodone is combined with Agomelatine.	Approved, Investigational
Aldosterone	The serum concentration of Aldosterone can be decreased when it is combined with Trazodone.	Experimental
Alfaxalone	The risk or severity of adverse effects can be increased when Trazodone is combined with Alfaxalone.	Vet Approved
Alfentanil	The risk or severity of adverse effects can be increased when Trazodone is combined with Alfentanil.	Approved, Illicit
Alimemazine	The risk or severity of adverse effects can be increased when Alimemazine is combined with Trazodone.	Approved, Vet Approved
Alitretinoin	The serum concentration of Alitretinoin can be decreased when it is combined with Trazodone.	Approved, Investigational
Allopregnanolone	The risk or severity of adverse effects can be increased when Trazodone is combined with Sage 547.	Investigational
Almotriptan	The risk or severity of adverse effects can be increased when Trazodone is combined with Almotriptan.	Approved, Investigational
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Trazodone is combined with Alphacetylmethadol.	Experimental, Illicit
Alprazolam	The risk or severity of adverse effects can be increased when Alprazolam is combined with Trazodone.	Approved, Illicit, Investigational
Ambrisentan	The serum concentration of Ambrisentan can be decreased when it is combined with Trazodone.	Approved, Investigational
Amiodarone	The metabolism of Trazodone can be decreased when combined with Amiodarone.	Approved, Investigational
Amisulpride	The risk or severity of adverse effects can be increased when Trazodone is combined with Amisulpride.	Approved, Investigational
Amitriptyline	The risk or severity of adverse effects can be increased when Amitriptyline is combined with Trazodone.	Approved
Amobarbital	The risk or severity of adverse effects can be increased when Trazodone is combined with Amobarbital.	Approved, Illicit
Amoxapine	The risk or severity of adverse effects can be increased when Amoxapine is combined with Trazodone.	Approved
Amperozide	The risk or severity of adverse effects can be increased when Trazodone is combined with Amperozide.	Experimental
Anagrelide	Trazodone may increase the QTc-prolonging activities of Anagrelide.	Approved
Apixaban	The serum concentration of Apixaban can be decreased when it is combined with Trazodone.	Approved
Aprepitant	The serum concentration of Trazodone can be increased when it is combined with Aprepitant.	Approved, Investigational
Aripiprazole	The risk or severity of adverse effects can be increased when Trazodone is combined with Aripiprazole.	Approved, Investigational
Arsenic trioxide	Trazodone may increase the QTc-prolonging activities of Arsenic trioxide.	Approved, Investigational
Artemether	Trazodone may increase the QTc-prolonging activities of Artemether.	Approved
Articaine	The risk or severity of adverse effects can be increased when Trazodone is combined with Articaine.	Approved
Asenapine	Trazodone may increase the QTc-prolonging activities of Asenapine.	Approved
Atazanavir	The serum concentration of Trazodone can be increased when it is combined with Atazanavir.	Approved, Investigational
Atenolol	The serum concentration of Atenolol can be decreased when it is combined with Trazodone.	Approved
Atomoxetine	The metabolism of Trazodone can be decreased when combined with Atomoxetine.	Approved
Axitinib	The serum concentration of Axitinib can be decreased when it is combined with Trazodone.	Approved, Investigational
Azelastine	Trazodone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.	Approved
Azelastine	The risk or severity of adverse effects can be increased when Trazodone is combined with Azelastine.	Approved
Azithromycin	Trazodone may increase the QTc-prolonging activities of Azithromycin.	Approved
Baclofen	The risk or severity of adverse effects can be increased when Trazodone is combined with Baclofen.	Approved
Barbital	The risk or severity of adverse effects can be increased when Trazodone is combined with Barbital.	Illicit
Bedaquiline	Trazodone may increase the QTc-prolonging activities of Bedaquiline.	Approved
Benmoxin	The risk or severity of adverse effects can be increased when Benmoxin is combined with Trazodone.	Withdrawn
Benperidol	The risk or severity of adverse effects can be increased when Trazodone is combined with Benperidol.	Investigational
Benzocaine	The risk or severity of adverse effects can be increased when Trazodone is combined with Benzocaine.	Approved
Benzyl alcohol	The risk or severity of adverse effects can be increased when Trazodone is combined with Benzyl alcohol.	Approved
Betamethasone	The serum concentration of Betamethasone can be decreased when it is combined with Trazodone.	Approved, Vet Approved
Betaxolol	The metabolism of Trazodone can be decreased when combined with Betaxolol.	Approved
Bexarotene	The serum concentration of Trazodone can be decreased when it is combined with Bexarotene.	Approved, Investigational
Bifeprunox	The risk or severity of adverse effects can be increased when Trazodone is combined with Bifeprunox.	Investigational
BL-1020	The risk or severity of adverse effects can be increased when BL-1020 is combined with Trazodone.	Investigational
Boceprevir	The serum concentration of Trazodone can be increased when it is combined with Boceprevir.	Approved, Investigational
Bortezomib	The metabolism of Trazodone can be decreased when combined with Bortezomib.	Approved, Investigational
Bosentan	The serum concentration of Trazodone can be decreased when it is combined with Bosentan.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be decreased when it is combined with Trazodone.	Approved
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be decreased when it is combined with Trazodone.	Approved
Brexpiprazole	The risk or severity of adverse effects can be increased when Trazodone is combined with Brexpiprazole.	Approved
Brimonidine	The risk or severity of adverse effects can be increased when Trazodone is combined with Brimonidine.	Approved
Brimonidine	Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Trazodone.	Approved
Bromazepam	The risk or severity of adverse effects can be increased when Trazodone is combined with Bromazepam.	Approved, Illicit
Bromocriptine	The risk or severity of adverse effects can be increased when Trazodone is combined with Bromocriptine.	Approved, Investigational
Bromperidol	The risk or severity of adverse effects can be increased when Trazodone is combined with Bromperidol.	Investigational
Brompheniramine	The risk or severity of adverse effects can be increased when Trazodone is combined with Brompheniramine.	Approved
Brotizolam	The risk or severity of adverse effects can be increased when Trazodone is combined with Brotizolam.	Approved, Withdrawn
Bupivacaine	The risk or severity of adverse effects can be increased when Bupivacaine is combined with Trazodone.	Approved, Investigational
Buprenorphine	Trazodone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Bupropion	The metabolism of Trazodone can be decreased when combined with Bupropion.	Approved
Buspirone	Buspirone may increase the serotonergic activities of Trazodone.	Approved, Investigational
Butabarbital	The risk or severity of adverse effects can be increased when Butabarbital is combined with Trazodone.	Approved, Illicit
Butalbital	The risk or severity of adverse effects can be increased when Trazodone is combined with Butalbital.	Approved, Illicit
Butethal	The risk or severity of adverse effects can be increased when Trazodone is combined with Butethal.	Approved, Illicit
Butorphanol	The risk or severity of adverse effects can be increased when Butorphanol is combined with Trazodone.	Approved, Illicit, Vet Approved
Cabazitaxel	The serum concentration of Cabazitaxel can be decreased when it is combined with Trazodone.	Approved
Cabergoline	The risk or severity of adverse effects can be increased when Cabergoline is combined with Trazodone.	Approved
Caffeine	The serum concentration of Caffeine can be decreased when it is combined with Trazodone.	Approved
Camptothecin	The serum concentration of Camptothecin can be decreased when it is combined with Trazodone.	Experimental
Canagliflozin	The serum concentration of Canagliflozin can be decreased when it is combined with Trazodone.	Approved
Carbamazepine	The metabolism of Trazodone can be increased when combined with Carbamazepine.	Approved, Investigational
Carbinoxamine	The risk or severity of adverse effects can be increased when Trazodone is combined with Carbinoxamine.	Approved
Carfentanil	The risk or severity of adverse effects can be increased when Trazodone is combined with Carfentanil.	Illicit, Vet Approved
Carfilzomib	The serum concentration of Carfilzomib can be decreased when it is combined with Trazodone.	Approved
Cariprazine	The risk or severity of adverse effects can be increased when Trazodone is combined with Cariprazine.	Approved
Carisoprodol	The risk or severity of adverse effects can be increased when Trazodone is combined with Carisoprodol.	Approved
Caroxazone	The risk or severity of adverse effects can be increased when Caroxazone is combined with Trazodone.	Withdrawn
Celecoxib	The metabolism of Trazodone can be decreased when combined with Celecoxib.	Approved, Investigational
Ceritinib	The serum concentration of Trazodone can be increased when it is combined with Ceritinib.	Approved
Cerivastatin	The serum concentration of Cerivastatin can be decreased when it is combined with Trazodone.	Withdrawn
Cetirizine	The risk or severity of adverse effects can be increased when Trazodone is combined with Cetirizine.	Approved
Chloral hydrate	The risk or severity of adverse effects can be increased when Trazodone is combined with Chloral hydrate.	Approved, Illicit, Vet Approved
Chlordiazepoxide	The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Trazodone.	Approved, Illicit
Chlormezanone	The risk or severity of adverse effects can be increased when Trazodone is combined with Chlormezanone.	Approved, Withdrawn
Chloroprocaine	The risk or severity of adverse effects can be increased when Trazodone is combined with Chloroprocaine.	Approved
Chloroquine	Trazodone may increase the QTc-prolonging activities of Chloroquine.	Approved, Vet Approved
Chlorphenamine	The risk or severity of adverse effects can be increased when Trazodone is combined with Chlorphenamine.	Approved
Chlorpromazine	Trazodone may increase the QTc-prolonging activities of Chlorpromazine.	Approved, Vet Approved
Chlorprothixene	The risk or severity of adverse effects can be increased when Trazodone is combined with Chlorprothixene.	Approved, Withdrawn
Chlorzoxazone	The risk or severity of adverse effects can be increased when Trazodone is combined with Chlorzoxazone.	Approved
Cholecalciferol	The metabolism of Trazodone can be decreased when combined with Cholecalciferol.	Approved, Nutraceutical
Cimetidine	The serum concentration of Cimetidine can be decreased when it is combined with Trazodone.	Approved
Cinacalcet	The metabolism of Trazodone can be decreased when combined with Cinacalcet.	Approved
Cinchocaine	The risk or severity of adverse effects can be increased when Cinchocaine is combined with Trazodone.	Approved, Vet Approved
Ciprofloxacin	Trazodone may increase the QTc-prolonging activities of Ciprofloxacin.	Approved, Investigational
Cisapride	Trazodone may increase the QTc-prolonging activities of Cisapride.	Approved, Investigational, Withdrawn
Cisplatin	The serum concentration of Cisplatin can be decreased when it is combined with Trazodone.	Approved
Citalopram	Trazodone may increase the QTc-prolonging activities of Citalopram.	Approved
Clarithromycin	The metabolism of Trazodone can be decreased when combined with Clarithromycin.	Approved
Clemastine	The metabolism of Trazodone can be decreased when combined with Clemastine.	Approved
Clidinium	The risk or severity of adverse effects can be increased when Trazodone is combined with Clidinium.	Approved
Clobazam	The serum concentration of Clobazam can be decreased when it is combined with Trazodone.	Approved, Illicit
Clomifene	The serum concentration of Clomifene can be decreased when it is combined with Trazodone.	Approved, Investigational
Clomipramine	The risk or severity of adverse effects can be increased when Trazodone is combined with Clomipramine.	Approved, Vet Approved
Clonazepam	The risk or severity of adverse effects can be increased when Trazodone is combined with Clonazepam.	Approved, Illicit
Clonidine	The serum concentration of Clonidine can be decreased when it is combined with Trazodone.	Approved
Clopidogrel	The serum concentration of Clopidogrel can be decreased when it is combined with Trazodone.	Approved, Nutraceutical
Clorazepate	The risk or severity of adverse effects can be increased when Clorazepate is combined with Trazodone.	Approved, Illicit
Clotrimazole	The metabolism of Trazodone can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	Trazodone may increase the QTc-prolonging activities of Clozapine.	Approved
Cobicistat	The serum concentration of Trazodone can be increased when it is combined with Cobicistat.	Approved
Cobimetinib	The serum concentration of Cobimetinib can be decreased when it is combined with Trazodone.	Approved
Cocaine	The metabolism of Trazodone can be decreased when combined with Cocaine.	Approved, Illicit
Codeine	The risk or severity of adverse effects can be increased when Codeine is combined with Trazodone.	Approved, Illicit
Colchicine	The serum concentration of Colchicine can be decreased when it is combined with Trazodone.	Approved
Conivaptan	The serum concentration of Trazodone can be increased when it is combined with Conivaptan.	Approved, Investigational
Conjugated estrogens	The serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Trazodone.	Approved
Crizotinib	Trazodone may increase the QTc-prolonging activities of Crizotinib.	Approved
Cyamemazine	The risk or severity of adverse effects can be increased when Trazodone is combined with Cyamemazine.	Approved
Cyclizine	The risk or severity of adverse effects can be increased when Trazodone is combined with Cyclizine.	Approved
Cyclobenzaprine	The risk or severity of adverse effects can be increased when Trazodone is combined with Cyclobenzaprine.	Approved
Cyclosporine	The metabolism of Trazodone can be decreased when combined with Cyclosporine.	Approved, Investigational, Vet Approved
Cyproheptadine	The risk or severity of adverse effects can be increased when Trazodone is combined with Cyproheptadine.	Approved
Dabigatran etexilate	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Trazodone.	Approved
Dabrafenib	The serum concentration of Trazodone can be decreased when it is combined with Dabrafenib.	Approved
Dactinomycin	The serum concentration of Dactinomycin can be decreased when it is combined with Trazodone.	Approved
Dantrolene	The risk or severity of adverse effects can be increased when Trazodone is combined with Dantrolene.	Approved
Dapagliflozin	The serum concentration of Dapagliflozin can be decreased when it is combined with Trazodone.	Approved
Dapiprazole	The risk or severity of adverse effects can be increased when Dapiprazole is combined with Trazodone.	Approved
Dapoxetine	The risk or severity of adverse effects can be increased when Dapoxetine is combined with Trazodone.	Investigational
Darifenacin	The metabolism of Trazodone can be decreased when combined with Darifenacin.	Approved, Investigational
Darunavir	The serum concentration of Trazodone can be increased when it is combined with Darunavir.	Approved
Dasatinib	The serum concentration of Trazodone can be increased when it is combined with Dasatinib.	Approved, Investigational
Daunorubicin	The serum concentration of Daunorubicin can be decreased when it is combined with Trazodone.	Approved
Debrisoquin	The serum concentration of Debrisoquin can be decreased when it is combined with Trazodone.	Approved
Deferasirox	The serum concentration of Trazodone can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delavirdine	The metabolism of Trazodone can be decreased when combined with Delavirdine.	Approved
Deramciclane	The risk or severity of adverse effects can be increased when Trazodone is combined with deramciclane.	Investigational
Desflurane	The risk or severity of adverse effects can be increased when Trazodone is combined with Desflurane.	Approved
Desipramine	The risk or severity of adverse effects can be increased when Trazodone is combined with Desipramine.	Approved
Desloratadine	The risk or severity of adverse effects can be increased when Trazodone is combined with Desloratadine.	Approved, Investigational
Desvenlafaxine	The risk or severity of adverse effects can be increased when Trazodone is combined with Desvenlafaxine.	Approved
Dexamethasone	The serum concentration of Trazodone can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexbrompheniramine	The risk or severity of adverse effects can be increased when Trazodone is combined with Dexbrompheniramine.	Approved
Dexmedetomidine	The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Trazodone.	Approved, Vet Approved
Dextromethorphan	The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Trazodone.	Approved
Dextromoramide	The risk or severity of adverse effects can be increased when Trazodone is combined with Dextromoramide.	Experimental, Illicit
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Trazodone.	Approved, Illicit, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Trazodone is combined with Dezocine.	Approved
Diazepam	The serum concentration of Diazepam can be decreased when it is combined with Trazodone.	Approved, Illicit, Vet Approved
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be decreased when it is combined with Trazodone.	Approved
Difenoxin	The risk or severity of adverse effects can be increased when Trazodone is combined with Difenoxin.	Approved, Illicit
Digitoxin	The serum concentration of Digitoxin can be decreased when it is combined with Trazodone.	Approved
Digoxin	The serum concentration of Digoxin can be decreased when it is combined with Trazodone.	Approved
Dihydrocodeine	The risk or severity of adverse effects can be increased when Trazodone is combined with Dihydrocodeine.	Approved, Illicit
Dihydroergotamine	The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Trazodone.	Approved
Dihydroetorphine	The risk or severity of adverse effects can be increased when Trazodone is combined with Dihydroetorphine.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Trazodone is combined with Dihydromorphine.	Experimental, Illicit
Dihydrotestosterone	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Trazodone.	Illicit
Diltiazem	The metabolism of Trazodone can be decreased when combined with Diltiazem.	Approved
Dimenhydrinate	The risk or severity of adverse effects can be increased when Trazodone is combined with Dimenhydrinate.	Approved
Diphenhydramine	The metabolism of Trazodone can be decreased when combined with Diphenhydramine.	Approved
Diphenoxylate	The risk or severity of adverse effects can be increased when Trazodone is combined with Diphenoxylate.	Approved, Illicit
Dipyridamole	The serum concentration of Dipyridamole can be decreased when it is combined with Trazodone.	Approved
Disopyramide	Trazodone may increase the QTc-prolonging activities of Disopyramide.	Approved
Docetaxel	The serum concentration of Docetaxel can be decreased when it is combined with Trazodone.	Approved, Investigational
Dofetilide	Trazodone may increase the QTc-prolonging activities of Dofetilide.	Approved
Dolasetron	Trazodone may increase the QTc-prolonging activities of Dolasetron.	Approved
Domperidone	Trazodone may increase the QTc-prolonging activities of Domperidone.	Approved, Investigational, Vet Approved
Doxepin	The risk or severity of adverse effects can be increased when Trazodone is combined with Doxepin.	Approved
Doxorubicin	The serum concentration of Doxorubicin can be decreased when it is combined with Trazodone.	Approved, Investigational
Doxycycline	The metabolism of Trazodone can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Doxylamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Trazodone.	Approved, Vet Approved
Dronabinol	Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Trazodone.	Approved, Illicit
Dronedarone	Trazodone may increase the QTc-prolonging activities of Dronedarone.	Approved
Droperidol	Droperidol may increase the central nervous system depressant (CNS depressant) activities of Trazodone.	Approved, Vet Approved
Drotebanol	The risk or severity of adverse effects can be increased when Trazodone is combined with Drotebanol.	Experimental, Illicit
Duloxetine	The risk or severity of adverse effects can be increased when Duloxetine is combined with Trazodone.	Approved
Dyclonine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Trazodone.	Approved
Ecgonine	The risk or severity of adverse effects can be increased when Trazodone is combined with Ecgonine.	Experimental, Illicit
Ecopipam	The risk or severity of adverse effects can be increased when Trazodone is combined with Ecopipam.	Investigational
Edoxaban	The serum concentration of Edoxaban can be decreased when it is combined with Trazodone.	Approved
Efavirenz	The serum concentration of Trazodone can be decreased when it is combined with Efavirenz.	Approved, Investigational
Eletriptan	The risk or severity of adverse effects can be increased when Eletriptan is combined with Trazodone.	Approved, Investigational
Eliglustat	Trazodone may increase the QTc-prolonging activities of Eliglustat.	Approved
Eltanolone	The risk or severity of adverse effects can be increased when Trazodone is combined with Pregnanolone.	Investigational
Enflurane	The risk or severity of adverse effects can be increased when Enflurane is combined with Trazodone.	Approved, Vet Approved
Entacapone	The risk or severity of adverse effects can be increased when Trazodone is combined with Entacapone.	Approved, Investigational
Enzalutamide	The serum concentration of Trazodone can be decreased when it is combined with Enzalutamide.	Approved
Epinastine	The serum concentration of Epinastine can be decreased when it is combined with Trazodone.	Approved, Investigational
Ergoloid mesylate	The risk or severity of adverse effects can be increased when Trazodone is combined with Ergoloid mesylate.	Approved
Ergonovine	The risk or severity of adverse effects can be increased when Trazodone is combined with Ergonovine.	Approved
Ergotamine	The risk or severity of adverse effects can be increased when Trazodone is combined with Ergotamine.	Approved
Erlotinib	The serum concentration of Erlotinib can be decreased when it is combined with Trazodone.	Approved, Investigational
Erythromycin	Trazodone may increase the QTc-prolonging activities of Erythromycin.	Approved, Vet Approved
Escitalopram	Trazodone may increase the QTc-prolonging activities of Escitalopram.	Approved, Investigational
Eslicarbazepine acetate	The serum concentration of Trazodone can be decreased when it is combined with Eslicarbazepine acetate.	Approved
Estazolam	The risk or severity of adverse effects can be increased when Trazodone is combined with Estazolam.	Approved, Illicit
Estradiol	The serum concentration of Estradiol can be decreased when it is combined with Trazodone.	Approved, Investigational, Vet Approved
Estriol	The serum concentration of Estriol can be decreased when it is combined with Trazodone.	Approved, Vet Approved
Estrone	The serum concentration of Estrone can be decreased when it is combined with Trazodone.	Approved
Eszopiclone	The risk or severity of adverse effects can be increased when Eszopiclone is combined with Trazodone.	Approved
Ethanol	The risk or severity of adverse effects can be increased when Ethanol is combined with Trazodone.	Approved
Ethchlorvynol	The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trazodone.	Approved, Illicit, Withdrawn
Ethinyl Estradiol	The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Trazodone.	Approved
Ethosuximide	The risk or severity of adverse effects can be increased when Trazodone is combined with Ethosuximide.	Approved
Ethotoin	The risk or severity of adverse effects can be increased when Trazodone is combined with Ethotoin.	Approved
Ethyl carbamate	The risk or severity of adverse effects can be increased when Trazodone is combined with Ethyl carbamate.	Withdrawn
Ethyl loflazepate	The risk or severity of adverse effects can be increased when Trazodone is combined with Ethyl loflazepate.	Approved, Illicit
Ethylmorphine	The risk or severity of adverse effects can be increased when Trazodone is combined with Ethylmorphine.	Approved, Illicit
Etidocaine	The risk or severity of adverse effects can be increased when Trazodone is combined with Etidocaine.	Approved
Etifoxine	The risk or severity of adverse effects can be increased when Trazodone is combined with Etifoxine.	Withdrawn
Etizolam	The risk or severity of adverse effects can be increased when Trazodone is combined with Etizolam.	Approved
Etomidate	The risk or severity of adverse effects can be increased when Etomidate is combined with Trazodone.	Approved
Etoperidone	Etoperidone may increase the serotonergic activities of Trazodone.	Approved
Etoposide	The serum concentration of Etoposide can be decreased when it is combined with Trazodone.	Approved
Etorphine	The risk or severity of adverse effects can be increased when Trazodone is combined with Etorphine.	Illicit, Vet Approved
Etravirine	The serum concentration of Trazodone can be decreased when it is combined with Etravirine.	Approved
Ezetimibe	The serum concentration of Ezetimibe can be decreased when it is combined with Trazodone.	Approved
Ezogabine	The risk or severity of adverse effects can be increased when Trazodone is combined with Ezogabine.	Approved
Felbamate	The risk or severity of adverse effects can be increased when Trazodone is combined with Felbamate.	Approved
Fencamfamine	The risk or severity of adverse effects can be increased when Trazodone is combined with Fencamfamine.	Approved, Illicit, Withdrawn
Fentanyl	The risk or severity of adverse effects can be increased when Trazodone is combined with Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fesoterodine	The serum concentration of Fesoterodine can be decreased when it is combined with Trazodone.	Approved
Fexofenadine	The serum concentration of Fexofenadine can be decreased when it is combined with Trazodone.	Approved
Fidaxomicin	The serum concentration of Fidaxomicin can be decreased when it is combined with Trazodone.	Approved
Flecainide	Trazodone may increase the QTc-prolonging activities of Flecainide.	Approved, Withdrawn
Flibanserin	The risk or severity of adverse effects can be increased when Trazodone is combined with Flibanserin.	Approved
Fluconazole	The metabolism of Trazodone can be decreased when combined with Fluconazole.	Approved
Fludiazepam	The risk or severity of adverse effects can be increased when Trazodone is combined with Fludiazepam.	Approved, Illicit
Flunarizine	The risk or severity of adverse effects can be increased when Trazodone is combined with Flunarizine.	Approved
Flunitrazepam	The risk or severity of adverse effects can be increased when Trazodone is combined with Flunitrazepam.	Approved, Illicit
Fluoxetine	Trazodone may increase the QTc-prolonging activities of Fluoxetine.	Approved, Vet Approved
Flupentixol	Trazodone may increase the QTc-prolonging activities of Flupentixol.	Approved, Withdrawn
Fluphenazine	The risk or severity of adverse effects can be increased when Fluphenazine is combined with Trazodone.	Approved
Flurazepam	The risk or severity of adverse effects can be increased when Trazodone is combined with Flurazepam.	Approved, Illicit
Fluspirilene	The risk or severity of adverse effects can be increased when Trazodone is combined with Fluspirilene.	Approved
Fluticasone furoate	The serum concentration of Fluticasone furoate can be decreased when it is combined with Trazodone.	Approved
Fluticasone propionate	The risk or severity of adverse effects can be increased when Trazodone is combined with Fluticasone Propionate.	Approved
Fluvoxamine	The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Trazodone.	Approved, Investigational
Fosamprenavir	The serum concentration of Trazodone can be increased when it is combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Trazodone can be increased when it is combined with Fosaprepitant.	Approved
Fosphenytoin	The serum concentration of Trazodone can be decreased when it is combined with Fosphenytoin.	Approved
Fospropofol	The risk or severity of adverse effects can be increased when Trazodone is combined with Fospropofol.	Approved, Illicit
Frovatriptan	The risk or severity of adverse effects can be increased when Trazodone is combined with Frovatriptan.	Approved, Investigational
Furazolidone	The risk or severity of adverse effects can be increased when Furazolidone is combined with Trazodone.	Approved, Vet Approved
Fusidic Acid	The serum concentration of Trazodone can be increased when it is combined with Fusidic Acid.	Approved
Gabapentin	The risk or severity of adverse effects can be increased when Trazodone is combined with Gabapentin.	Approved, Investigational
Gabapentin Enacarbil	The risk or severity of adverse effects can be increased when Trazodone is combined with gabapentin enacarbil.	Approved
Gadobenic acid	Trazodone may increase the QTc-prolonging activities of Gadobenic acid.	Approved
Gamma Hydroxybutyric Acid	The risk or severity of adverse effects can be increased when Trazodone is combined with Gamma Hydroxybutyric Acid.	Approved, Illicit
Gefitinib	The serum concentration of Gefitinib can be decreased when it is combined with Trazodone.	Approved, Investigational
Gemcitabine	The serum concentration of Gemcitabine can be decreased when it is combined with Trazodone.	Approved
Gemifloxacin	Trazodone may increase the QTc-prolonging activities of Gemifloxacin.	Approved, Investigational
Gepirone	The risk or severity of adverse effects can be increased when Trazodone is combined with Gepirone.	Investigational
Glutethimide	The risk or severity of adverse effects can be increased when Trazodone is combined with Glutethimide.	Approved, Illicit
Goserelin	Trazodone may increase the QTc-prolonging activities of Goserelin.	Approved
Granisetron	Trazodone may increase the QTc-prolonging activities of Granisetron.	Approved, Investigational
Grazoprevir	The serum concentration of Grazoprevir can be decreased when it is combined with Trazodone.	Approved
Grepafloxacin	The serum concentration of Grepafloxacin can be decreased when it is combined with Trazodone.	Withdrawn
Guanfacine	The risk or severity of adverse effects can be increased when Trazodone is combined with Guanfacine.	Approved, Investigational
Halazepam	The risk or severity of adverse effects can be increased when Trazodone is combined with Halazepam.	Approved, Illicit, Withdrawn
Haloperidol	Trazodone may increase the QTc-prolonging activities of Haloperidol.	Approved
Halothane	The risk or severity of adverse effects can be increased when Trazodone is combined with Halothane.	Approved, Vet Approved
Heroin	The risk or severity of adverse effects can be increased when Trazodone is combined with Heroin.	Approved, Illicit
Hexobarbital	The risk or severity of adverse effects can be increased when Trazodone is combined with Hexobarbital.	Approved
Hydracarbazine	The risk or severity of adverse effects can be increased when Hydracarbazine is combined with Trazodone.	Experimental
Hydrocodone	Trazodone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.	Approved, Illicit
Hydrocortisone	The serum concentration of Hydrocortisone can be decreased when it is combined with Trazodone.	Approved, Vet Approved
Hydromorphone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Trazodone.	Approved, Illicit
Hydroxyzine	Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Trazodone.	Approved
Ibuprofen	The serum concentration of Ibuprofen can be decreased when it is combined with Trazodone.	Approved
Ibutilide	Trazodone may increase the QTc-prolonging activities of Ibutilide.	Approved
Idelalisib	The serum concentration of Trazodone can be increased when it is combined with Idelalisib.	Approved
Iloperidone	Trazodone may increase the QTc-prolonging activities of Iloperidone.	Approved
Imatinib	The metabolism of Trazodone can be decreased when combined with Imatinib.	Approved
Imipramine	The risk or severity of adverse effects can be increased when Imipramine is combined with Trazodone.	Approved
Indacaterol	The serum concentration of Indacaterol can be decreased when it is combined with Trazodone.	Approved
Indalpine	Indalpine may increase the serotonergic activities of Trazodone.	Investigational, Withdrawn
Indinavir	The serum concentration of Trazodone can be increased when it is combined with Indinavir.	Approved
Indomethacin	The serum concentration of Indomethacin can be decreased when it is combined with Trazodone.	Approved, Investigational
Iproclozide	The risk or severity of adverse effects can be increased when Iproclozide is combined with Trazodone.	Withdrawn
Iproniazid	The risk or severity of adverse effects can be increased when Iproniazid is combined with Trazodone.	Withdrawn
Irinotecan	The serum concentration of Irinotecan can be decreased when it is combined with Trazodone.	Approved, Investigational
Isavuconazonium	The metabolism of Trazodone can be decreased when combined with Isavuconazonium.	Approved, Investigational
Isocarboxazid	The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Trazodone.	Approved
Isoflurane	The risk or severity of adverse effects can be increased when Trazodone is combined with Isoflurane.	Approved, Vet Approved
Isoniazid	The metabolism of Trazodone can be decreased when combined with Isoniazid.	Approved
Isradipine	The metabolism of Trazodone can be decreased when combined with Isradipine.	Approved
Itraconazole	The metabolism of Trazodone can be decreased when combined with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of Trazodone can be increased when it is combined with Ivacaftor.	Approved
Ivermectin	The serum concentration of Ivermectin can be decreased when it is combined with Trazodone.	Approved, Vet Approved
Ketamine	The risk or severity of adverse effects can be increased when Trazodone is combined with Ketamine.	Approved, Vet Approved
Ketazolam	The serum concentration of Ketazolam can be decreased when it is combined with Trazodone.	Approved
Ketobemidone	The risk or severity of adverse effects can be increased when Trazodone is combined with Ketobemidone.	Approved
Ketoconazole	The metabolism of Trazodone can be decreased when combined with Ketoconazole.	Approved, Investigational
Lamivudine	The serum concentration of Lamivudine can be decreased when it is combined with Trazodone.	Approved, Investigational
Lamotrigine	The serum concentration of Lamotrigine can be decreased when it is combined with Trazodone.	Approved, Investigational
Lansoprazole	The serum concentration of Lansoprazole can be decreased when it is combined with Trazodone.	Approved, Investigational
Ledipasvir	The serum concentration of Ledipasvir can be decreased when it is combined with Trazodone.	Approved
Lenalidomide	The serum concentration of Lenalidomide can be decreased when it is combined with Trazodone.	Approved
Lenvatinib	Trazodone may increase the QTc-prolonging activities of Lenvatinib.	Approved
Leuprolide	Trazodone may increase the QTc-prolonging activities of Leuprolide.	Approved, Investigational
Levetiracetam	The serum concentration of Levetiracetam can be decreased when it is combined with Trazodone.	Approved, Investigational
Levobupivacaine	The risk or severity of adverse effects can be increased when Trazodone is combined with Levobupivacaine.	Approved
Levocabastine	The risk or severity of adverse effects can be increased when Trazodone is combined with Levocabastine.	Approved
Levocetirizine	The risk or severity of adverse effects can be increased when Trazodone is combined with Levocetirizine.	Approved
Levodopa	The risk or severity of adverse effects can be increased when Trazodone is combined with Levodopa.	Approved
Levofloxacin	Trazodone may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Levomethadyl Acetate	The risk or severity of adverse effects can be increased when Trazodone is combined with Levomethadyl Acetate.	Approved
Levomilnacipran	The risk or severity of adverse effects can be increased when Trazodone is combined with Levomilnacipran.	Approved
Levorphanol	The risk or severity of adverse effects can be increased when Trazodone is combined with Levorphanol.	Approved
Lidocaine	The risk or severity of adverse effects can be increased when Lidocaine is combined with Trazodone.	Approved, Vet Approved
Linagliptin	The serum concentration of Linagliptin can be decreased when it is combined with Trazodone.	Approved
Linezolid	Linezolid may increase the serotonergic activities of Trazodone.	Approved, Investigational
Lithium	The risk or severity of adverse effects can be increased when Trazodone is combined with Lithium.	Approved
Lofentanil	The risk or severity of adverse effects can be increased when Trazodone is combined with Lofentanil.	Illicit
Loperamide	The serum concentration of Loperamide can be decreased when it is combined with Trazodone.	Approved
Lopinavir	Lopinavir may increase the QTc-prolonging activities of Trazodone.	Approved
Loratadine	The risk or severity of adverse effects can be increased when Trazodone is combined with Loratadine.	Approved
Lorazepam	The risk or severity of adverse effects can be increased when Lorazepam is combined with Trazodone.	Approved
Lorcaserin	The risk or severity of adverse effects can be increased when Trazodone is combined with Lorcaserin.	Approved
Losartan	The serum concentration of Losartan can be decreased when it is combined with Trazodone.	Approved
Lovastatin	The metabolism of Trazodone can be decreased when combined with Lovastatin.	Approved, Investigational
Loxapine	The risk or severity of adverse effects can be increased when Loxapine is combined with Trazodone.	Approved
Luliconazole	The serum concentration of Trazodone can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The metabolism of Trazodone can be increased when combined with Lumacaftor.	Approved
Lumefantrine	Trazodone may increase the QTc-prolonging activities of Lumefantrine.	Approved
Lurasidone	The risk or severity of adverse effects can be increased when Trazodone is combined with Lurasidone.	Approved
Magnesium Sulfate	Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Trazodone.	Approved, Vet Approved
Mannitol	The serum concentration of Mannitol can be decreased when it is combined with Trazodone.	Approved, Investigational
Maprotiline	The risk or severity of adverse effects can be increased when Trazodone is combined with Maprotiline.	Approved
Mebanazine	The risk or severity of adverse effects can be increased when Mebanazine is combined with Trazodone.	Withdrawn
Meclizine	The risk or severity of adverse effects can be increased when Trazodone is combined with Meclizine.	Approved
Melatonin	The risk or severity of adverse effects can be increased when Trazodone is combined with Melatonin.	Approved, Nutraceutical, Vet Approved
Melperone	The risk or severity of adverse effects can be increased when Trazodone is combined with Melperone.	Approved
Mepivacaine	The risk or severity of adverse effects can be increased when Trazodone is combined with Mepivacaine.	Approved, Vet Approved
Meprobamate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Trazodone.	Approved, Illicit
Mesoridazine	The risk or severity of adverse effects can be increased when Mesoridazine is combined with Trazodone.	Approved
Metaxalone	The risk or severity of adverse effects can be increased when Trazodone is combined with Metaxalone.	Approved
Methadone	The risk or severity of adverse effects can be increased when Methadone is combined with Trazodone.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Trazodone is combined with Methadyl Acetate.	Approved, Illicit
Methapyrilene	The risk or severity of adverse effects can be increased when Trazodone is combined with Methapyrilene.	Withdrawn
Methaqualone	The risk or severity of adverse effects can be increased when Trazodone is combined with Methaqualone.	Illicit, Withdrawn
Methocarbamol	The risk or severity of adverse effects can be increased when Trazodone is combined with Methocarbamol.	Approved, Vet Approved
Methohexital	The risk or severity of adverse effects can be increased when Methohexital is combined with Trazodone.	Approved
Methotrexate	The serum concentration of Methotrexate can be decreased when it is combined with Trazodone.	Approved
Methotrimeprazine	Trazodone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.	Approved
Methoxyflurane	The risk or severity of adverse effects can be increased when Trazodone is combined with Methoxyflurane.	Approved, Vet Approved
Methsuximide	The risk or severity of adverse effects can be increased when Trazodone is combined with Methsuximide.	Approved
Methylecgonine	The risk or severity of adverse effects can be increased when Trazodone is combined with ECGONINE METHYL ESTER.	Experimental
Methylene blue	Trazodone may increase the serotonergic activities of Methylene blue.	Investigational
Methylphenobarbital	The risk or severity of adverse effects can be increased when Trazodone is combined with Methylphenobarbital.	Approved
Methylprednisolone	The serum concentration of Methylprednisolone can be decreased when it is combined with Trazodone.	Approved, Vet Approved
Metoclopramide	The risk or severity of adverse effects can be increased when Trazodone is combined with Metoclopramide.	Approved, Investigational
Metoprolol	The serum concentration of Metoprolol can be decreased when it is combined with Trazodone.	Approved, Investigational
Metyrosine	Trazodone may increase the sedative activities of Metyrosine.	Approved
Midazolam	The serum concentration of Midazolam can be decreased when it is combined with Trazodone.	Approved, Illicit
Mifepristone	Mifepristone may increase the QTc-prolonging activities of Trazodone.	Approved, Investigational
Milnacipran	The risk or severity of adverse effects can be increased when Trazodone is combined with Milnacipran.	Approved
Minaprine	The risk or severity of adverse effects can be increased when Minaprine is combined with Trazodone.	Approved
Minocycline	Minocycline may increase the central nervous system depressant (CNS depressant) activities of Trazodone.	Approved, Investigational
Mirabegron	The serum concentration of Mirabegron can be decreased when it is combined with Trazodone.	Approved
Mirtazapine	Trazodone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.	Approved
Mitotane	The serum concentration of Trazodone can be decreased when it is combined with Mitotane.	Approved
Mitoxantrone	The serum concentration of Mitoxantrone can be decreased when it is combined with Trazodone.	Approved, Investigational
Moclobemide	The risk or severity of adverse effects can be increased when Moclobemide is combined with Trazodone.	Approved
Modafinil	The serum concentration of Trazodone can be decreased when it is combined with Modafinil.	Approved, Investigational
Molindone	The risk or severity of adverse effects can be increased when Trazodone is combined with Molindone.	Approved
Moricizine	The risk or severity of adverse effects can be increased when Moricizine is combined with Trazodone.	Approved, Withdrawn
Morphine	The serum concentration of Morphine can be decreased when it is combined with Trazodone.	Approved, Investigational
Moxifloxacin	Trazodone may increase the QTc-prolonging activities of Moxifloxacin.	Approved, Investigational
Mycophenolate mofetil	The serum concentration of Mycophenolate mofetil can be decreased when it is combined with Trazodone.	Approved, Investigational
Nabilone	Nabilone may increase the central nervous system depressant (CNS depressant) activities of Trazodone.	Approved, Investigational
Nadolol	The serum concentration of Nadolol can be decreased when it is combined with Trazodone.	Approved
Nafcillin	The serum concentration of Trazodone can be decreased when it is combined with Nafcillin.	Approved
Nalbuphine	The risk or severity of adverse effects can be increased when Trazodone is combined with Nalbuphine.	Approved
Naloxone	The serum concentration of Naloxone can be decreased when it is combined with Trazodone.	Approved, Vet Approved
Naratriptan	The risk or severity of adverse effects can be increased when Trazodone is combined with Naratriptan.	Approved, Investigational
Nefazodone	The metabolism of Trazodone can be decreased when combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The serum concentration of Trazodone can be increased when it is combined with Nelfinavir.	Approved
Netupitant	The serum concentration of Trazodone can be increased when it is combined with Netupitant.	Approved
Nevirapine	The metabolism of Trazodone can be increased when combined with Nevirapine.	Approved
Nialamide	The risk or severity of adverse effects can be increased when Nialamide is combined with Trazodone.	Withdrawn
Nicardipine	The serum concentration of Nicardipine can be decreased when it is combined with Trazodone.	Approved
Nifedipine	The serum concentration of Nifedipine can be decreased when it is combined with Trazodone.	Approved
Nilotinib	Trazodone may increase the QTc-prolonging activities of Nilotinib.	Approved, Investigational
Nintedanib	The serum concentration of Nintedanib can be decreased when it is combined with Trazodone.	Approved
Nitrazepam	The risk or severity of adverse effects can be increased when Trazodone is combined with Nitrazepam.	Approved
Nitrous oxide	The risk or severity of adverse effects can be increased when Trazodone is combined with Nitrous oxide.	Approved, Vet Approved
Nizatidine	The serum concentration of Nizatidine can be decreased when it is combined with Trazodone.	Approved
Norflurane	The risk or severity of adverse effects can be increased when Trazodone is combined with 1,1,1,2 Tetrafluoroethane.	Investigational
Normethadone	The risk or severity of adverse effects can be increased when Trazodone is combined with Normethadone.	Approved, Illicit
Nortriptyline	The risk or severity of adverse effects can be increased when Nortriptyline is combined with Trazodone.	Approved
Octamoxin	The risk or severity of adverse effects can be increased when Octamoxin is combined with Trazodone.	Withdrawn
Ofloxacin	Trazodone may increase the QTc-prolonging activities of Ofloxacin.	Approved
Olanzapine	The serum concentration of Olanzapine can be decreased when it is combined with Trazodone.	Approved, Investigational
Olaparib	The metabolism of Trazodone can be decreased when combined with Olaparib.	Approved
Olopatadine	The risk or severity of adverse effects can be increased when Trazodone is combined with Olopatadine.	Approved
Ombitasvir	The serum concentration of Ombitasvir can be decreased when it is combined with Trazodone.	Approved
Ondansetron	Trazodone may increase the QTc-prolonging activities of Ondansetron.	Approved
Opium	The risk or severity of adverse effects can be increased when Trazodone is combined with Opium.	Approved, Illicit
Orphenadrine	Trazodone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.	Approved
Osanetant	The risk or severity of adverse effects can be increased when Trazodone is combined with Osanetant.	Investigational
Osimertinib	The serum concentration of Trazodone can be increased when it is combined with Osimertinib.	Approved
Oxazepam	The risk or severity of adverse effects can be increased when Trazodone is combined with Oxazepam.	Approved
Oxethazaine	The risk or severity of adverse effects can be increased when Trazodone is combined with Oxetacaine.	Investigational
Oxprenolol	The risk or severity of adverse effects can be increased when Trazodone is combined with Oxprenolol.	Approved
Oxybuprocaine	The risk or severity of adverse effects can be increased when Trazodone is combined with Oxybuprocaine.	Approved
Oxycodone	The risk or severity of adverse effects can be increased when Oxycodone is combined with Trazodone.	Approved, Illicit, Investigational
Oxymorphone	The risk or severity of adverse effects can be increased when Trazodone is combined with Oxymorphone.	Approved, Investigational, Vet Approved
Paclitaxel	The serum concentration of Paclitaxel can be decreased when it is combined with Trazodone.	Approved, Vet Approved
Palbociclib	The serum concentration of Trazodone can be increased when it is combined with Palbociclib.	Approved
Paliperidone	Trazodone may increase the QTc-prolonging activities of Paliperidone.	Approved
Palonosetron	Palonosetron may increase the serotonergic activities of Trazodone.	Approved, Investigational
Panobinostat	The serum concentration of Trazodone can be increased when it is combined with Panobinostat.	Approved, Investigational
Paraldehyde	Trazodone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.	Approved
Pargyline	The risk or severity of adverse effects can be increased when Pargyline is combined with Trazodone.	Approved
Paroxetine	The metabolism of Trazodone can be decreased when combined with Paroxetine.	Approved, Investigational
Pazopanib	Trazodone may increase the QTc-prolonging activities of Pazopanib.	Approved
Peginterferon alfa-2b	The serum concentration of Trazodone can be decreased when it is combined with Peginterferon alfa-2b.	Approved
Pentamidine	Trazodone may increase the QTc-prolonging activities of Pentamidine.	Approved
Pentazocine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Trazodone.	Approved, Vet Approved
Pentobarbital	The metabolism of Trazodone can be increased when combined with Pentobarbital.	Approved, Vet Approved
Perampanel	Perampanel may increase the central nervous system depressant (CNS depressant) activities of Trazodone.	Approved
Perazine	The risk or severity of adverse effects can be increased when Perazine is combined with Trazodone.	Investigational
Perflutren	Trazodone may increase the QTc-prolonging activities of Perflutren.	Approved
Perospirone	The risk or severity of adverse effects can be increased when Trazodone is combined with Perospirone.	Approved
Perphenazine	The risk or severity of adverse effects can be increased when Perphenazine is combined with Trazodone.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Pethidine is combined with Trazodone.	Approved
Phenelzine	The risk or severity of adverse effects can be increased when Phenelzine is combined with Trazodone.	Approved
Pheniprazine	The risk or severity of adverse effects can be increased when Pheniprazine is combined with Trazodone.	Withdrawn
Phenobarbital	The metabolism of Trazodone can be increased when combined with Phenobarbital.	Approved
Phenoxypropazine	The risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Trazodone.	Withdrawn
Phenytoin	The serum concentration of Trazodone can be decreased when it is combined with Phenytoin.	Approved, Vet Approved
Pimozide	Trazodone may increase the QTc-prolonging activities of Pimozide.	Approved
Pipamperone	The risk or severity of adverse effects can be increased when Trazodone is combined with Pipamperone.	Approved
Pipotiazine	The risk or severity of adverse effects can be increased when Trazodone is combined with Pipotiazine.	Approved
Piritramide	The risk or severity of adverse effects can be increased when Trazodone is combined with Piritramide.	Investigational
Pirlindole	The risk or severity of adverse effects can be increased when Pirlindole is combined with Trazodone.	Approved
Pitavastatin	The serum concentration of Pitavastatin can be decreased when it is combined with Trazodone.	Approved
Pivhydrazine	The risk or severity of adverse effects can be increased when Pivhydrazine is combined with Trazodone.	Withdrawn
Pomalidomide	The serum concentration of Pomalidomide can be decreased when it is combined with Trazodone.	Approved
Ponatinib	The serum concentration of Ponatinib can be decreased when it is combined with Trazodone.	Approved
Posaconazole	The metabolism of Trazodone can be decreased when combined with Posaconazole.	Approved, Investigational, Vet Approved
Pramipexole	Trazodone may increase the sedative activities of Pramipexole.	Approved, Investigational
Pramocaine	The risk or severity of adverse effects can be increased when Trazodone is combined with Pramocaine.	Approved
Pravastatin	The serum concentration of Pravastatin can be decreased when it is combined with Trazodone.	Approved
Prazepam	The risk or severity of adverse effects can be increased when Trazodone is combined with Prazepam.	Approved, Illicit
Prazosin	The serum concentration of Prazosin can be decreased when it is combined with Trazodone.	Approved
Prednisolone	The serum concentration of Prednisolone can be decreased when it is combined with Trazodone.	Approved, Vet Approved
Prednisone	The serum concentration of Prednisone can be decreased when it is combined with Trazodone.	Approved, Vet Approved
Pregabalin	The risk or severity of adverse effects can be increased when Pregabalin is combined with Trazodone.	Approved, Illicit, Investigational
Prilocaine	The risk or severity of adverse effects can be increased when Trazodone is combined with Prilocaine.	Approved
Primaquine	Trazodone may increase the QTc-prolonging activities of Primaquine.	Approved
Primidone	The metabolism of Trazodone can be increased when combined with Primidone.	Approved, Vet Approved
Procainamide	Trazodone may increase the QTc-prolonging activities of Procainamide.	Approved
Procaine	The risk or severity of adverse effects can be increased when Trazodone is combined with Procaine.	Approved, Investigational, Vet Approved
Procarbazine	The risk or severity of adverse effects can be increased when Trazodone is combined with Procarbazine.	Approved
Prochlorperazine	The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trazodone.	Approved, Vet Approved
Progesterone	The serum concentration of Progesterone can be decreased when it is combined with Trazodone.	Approved, Vet Approved
Promazine	Trazodone may increase the QTc-prolonging activities of Promazine.	Approved, Vet Approved
Promethazine	The risk or severity of adverse effects can be increased when Trazodone is combined with Promethazine.	Approved
Propafenone	Trazodone may increase the QTc-prolonging activities of Propafenone.	Approved
Proparacaine	The risk or severity of adverse effects can be increased when Trazodone is combined with Proparacaine.	Approved, Vet Approved
Propericiazine	The risk or severity of adverse effects can be increased when Trazodone is combined with Propericiazine.	Approved
Propofol	The risk or severity of adverse effects can be increased when Trazodone is combined with Propofol.	Approved, Investigational, Vet Approved
Propoxycaine	The risk or severity of adverse effects can be increased when Trazodone is combined with Propoxycaine.	Approved
Propranolol	The serum concentration of Propranolol can be decreased when it is combined with Trazodone.	Approved, Investigational
Prothipendyl	The risk or severity of adverse effects can be increased when Trazodone is combined with Prothipendyl.	Investigational
Protriptyline	The risk or severity of adverse effects can be increased when Protriptyline is combined with Trazodone.	Approved
Quazepam	The risk or severity of adverse effects can be increased when Trazodone is combined with Quazepam.	Approved, Illicit
Quetiapine	Trazodone may increase the QTc-prolonging activities of Quetiapine.	Approved
Quinidine	Trazodone may increase the QTc-prolonging activities of Quinidine.	Approved
Quinine	Trazodone may increase the QTc-prolonging activities of Quinine.	Approved
Raclopride	The risk or severity of adverse effects can be increased when Trazodone is combined with Raclopride.	Investigational
Ramelteon	The risk or severity of adverse effects can be increased when Trazodone is combined with Ramelteon.	Approved, Investigational
Ranitidine	The serum concentration of Ranitidine can be decreased when it is combined with Trazodone.	Approved
Ranolazine	The metabolism of Trazodone can be decreased when combined with Ranolazine.	Approved, Investigational
Rasagiline	The risk or severity of adverse effects can be increased when Rasagiline is combined with Trazodone.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Trazodone is combined with Remifentanil.	Approved
Remoxipride	The risk or severity of adverse effects can be increased when Remoxipride is combined with Trazodone.	Approved, Withdrawn
Reserpine	The serum concentration of Reserpine can be decreased when it is combined with Trazodone.	Approved
Rifabutin	The metabolism of Trazodone can be increased when combined with Rifabutin.	Approved
Rifampicin	The metabolism of Trazodone can be increased when combined with Rifampicin.	Approved
Rifapentine	The metabolism of Trazodone can be increased when combined with Rifapentine.	Approved
Risperidone	The serum concentration of Risperidone can be decreased when it is combined with Trazodone.	Approved, Investigational
Ritanserin	The risk or severity of adverse effects can be increased when Trazodone is combined with Ritanserin.	Investigational
Ritonavir	The serum concentration of Trazodone can be increased when it is combined with Ritonavir.	Approved, Investigational
Rivaroxaban	The serum concentration of Rivaroxaban can be decreased when it is combined with Trazodone.	Approved
Rizatriptan	The risk or severity of adverse effects can be increased when Trazodone is combined with Rizatriptan.	Approved
Rolapitant	The metabolism of Trazodone can be decreased when combined with Rolapitant.	Approved
Romidepsin	The serum concentration of Romidepsin can be decreased when it is combined with Trazodone.	Approved, Investigational
Ropinirole	Trazodone may increase the sedative activities of Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Ropivacaine is combined with Trazodone.	Approved
Rotigotine	Trazodone may increase the sedative activities of Rotigotine.	Approved
Rufinamide	The risk or severity of adverse effects can be increased when Rufinamide is combined with Trazodone.	Approved
Safrazine	The risk or severity of adverse effects can be increased when Safrazine is combined with Trazodone.	Withdrawn
Salicylic acid	The serum concentration of Salicylic acid can be decreased when it is combined with Trazodone.	Approved, Vet Approved
Saquinavir	Saquinavir may increase the QTc-prolonging activities of Trazodone.	Approved, Investigational
Scopolamine	The risk or severity of adverse effects can be increased when Trazodone is combined with Scopolamine.	Approved
Secobarbital	The risk or severity of adverse effects can be increased when Secobarbital is combined with Trazodone.	Approved, Vet Approved
Selegiline	The risk or severity of adverse effects can be increased when Selegiline is combined with Trazodone.	Approved, Investigational, Vet Approved
Selexipag	The serum concentration of Selexipag can be decreased when it is combined with Trazodone.	Approved
Sepranolone	The risk or severity of adverse effects can be increased when Trazodone is combined with Uc1010.	Investigational
Sertindole	The risk or severity of adverse effects can be increased when Trazodone is combined with Sertindole.	Approved, Withdrawn
Sertraline	The risk or severity of adverse effects can be increased when Trazodone is combined with Sertraline.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Trazodone is combined with Sevoflurane.	Approved, Vet Approved
Sildenafil	The metabolism of Trazodone can be decreased when combined with Sildenafil.	Approved, Investigational
Silodosin	The serum concentration of Silodosin can be decreased when it is combined with Trazodone.	Approved
Siltuximab	The serum concentration of Trazodone can be decreased when it is combined with Siltuximab.	Approved
Simeprevir	The serum concentration of Trazodone can be increased when it is combined with Simeprevir.	Approved
Sitagliptin	The serum concentration of Sitagliptin can be decreased when it is combined with Trazodone.	Approved, Investigational
Sodium oxybate	Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Trazodone.	Approved
Sofosbuvir	The serum concentration of Sofosbuvir can be decreased when it is combined with Trazodone.	Approved
Sorafenib	The serum concentration of Sorafenib can be decreased when it is combined with Trazodone.	Approved, Investigational
Sotalol	Trazodone may increase the QTc-prolonging activities of Sotalol.	Approved
Sparfloxacin	The serum concentration of Sparfloxacin can be decreased when it is combined with Trazodone.	Approved
Sphingosine	The serum concentration of Sphingosine can be decreased when it is combined with Trazodone.	Experimental
St. John's Wort	The serum concentration of Trazodone can be decreased when it is combined with St. John's Wort.	Nutraceutical
Stiripentol	The serum concentration of Trazodone can be increased when it is combined with Stiripentol.	Approved
Sufentanil	The risk or severity of adverse effects can be increased when Trazodone is combined with Sufentanil.	Approved, Investigational
Sulfisoxazole	Trazodone may increase the QTc-prolonging activities of Sulfisoxazole.	Approved, Vet Approved
Sulpiride	The risk or severity of adverse effects can be increased when Sulpiride is combined with Trazodone.	Approved
Sumatriptan	The risk or severity of adverse effects can be increased when Trazodone is combined with Sumatriptan.	Approved, Investigational
Suvorexant	Trazodone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.	Approved
Tacrolimus	The metabolism of Tacrolimus can be decreased when combined with Trazodone.	Approved, Investigational
Tacrolimus	The serum concentration of Tacrolimus can be decreased when it is combined with Trazodone.	Approved, Investigational
Tamoxifen	The serum concentration of Tamoxifen can be decreased when it is combined with Trazodone.	Approved
Tandospirone	The risk or severity of adverse effects can be increased when Trazodone is combined with Tandospirone.	Investigational
Tapentadol	Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Trazodone.	Approved
Tasimelteon	The risk or severity of adverse effects can be increased when Trazodone is combined with Tasimelteon.	Approved
Taurocholic Acid	The serum concentration of Taurocholic Acid can be decreased when it is combined with Trazodone.	Experimental
Technetium Tc-99m sestamibi	The serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Trazodone.	Approved
Tedizolid Phosphate	Tedizolid Phosphate may increase the serotonergic activities of Trazodone.	Approved
Telaprevir	The serum concentration of Trazodone can be increased when it is combined with Telaprevir.	Withdrawn
Telavancin	Trazodone may increase the QTc-prolonging activities of Telavancin.	Approved
Telithromycin	The metabolism of Trazodone can be decreased when combined with Telithromycin.	Approved
Temazepam	The risk or severity of adverse effects can be increased when Temazepam is combined with Trazodone.	Approved
Temsirolimus	The serum concentration of Temsirolimus can be decreased when it is combined with Trazodone.	Approved
Terbinafine	The metabolism of Trazodone can be decreased when combined with Terbinafine.	Approved, Investigational, Vet Approved
Tetrabenazine	Trazodone may increase the QTc-prolonging activities of Tetrabenazine.	Approved
Tetracaine	The risk or severity of adverse effects can be increased when Trazodone is combined with Tetracaine.	Approved, Vet Approved
Tetrodotoxin	The risk or severity of adverse effects can be increased when Trazodone is combined with Tetrodotoxin.	Investigational
Thalidomide	Trazodone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.	Approved, Investigational, Withdrawn
Thiamylal	The risk or severity of adverse effects can be increased when Trazodone is combined with Thiamylal.	Approved, Vet Approved
Thiethylperazine	The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Trazodone.	Withdrawn
Thiopental	The risk or severity of adverse effects can be increased when Thiopental is combined with Trazodone.	Approved, Vet Approved
Thioproperazine	The risk or severity of adverse effects can be increased when Trazodone is combined with Thioproperazine.	Approved
Thioridazine	Trazodone may increase the QTc-prolonging activities of Thioridazine.	Withdrawn
Thiothixene	The risk or severity of adverse effects can be increased when Trazodone is combined with Thiothixene.	Approved
Tiagabine	The risk or severity of adverse effects can be increased when Trazodone is combined with Tiagabine.	Approved
Tiapride	The risk or severity of adverse effects can be increased when Trazodone is combined with Tiapride.	Approved, Investigational
Ticagrelor	The serum concentration of Ticagrelor can be decreased when it is combined with Trazodone.	Approved
Ticlopidine	The metabolism of Trazodone can be decreased when combined with Ticlopidine.	Approved
Timolol	The serum concentration of Timolol can be decreased when it is combined with Trazodone.	Approved
Tipranavir	The serum concentration of Trazodone can be increased when it is combined with Tipranavir.	Approved, Investigational
Tizanidine	The risk or severity of adverse effects can be increased when Trazodone is combined with Tizanidine.	Approved
Tocilizumab	The serum concentration of Trazodone can be decreased when it is combined with Tocilizumab.	Approved
Tolcapone	The risk or severity of adverse effects can be increased when Trazodone is combined with Tolcapone.	Approved, Withdrawn
Toloxatone	The risk or severity of adverse effects can be increased when Toloxatone is combined with Trazodone.	Approved
Tolvaptan	The serum concentration of Tolvaptan can be decreased when it is combined with Trazodone.	Approved
Topiramate	The risk or severity of adverse effects can be increased when Trazodone is combined with Topiramate.	Approved
Topotecan	The serum concentration of Topotecan can be decreased when it is combined with Trazodone.	Approved, Investigational
Toremifene	Trazodone may increase the QTc-prolonging activities of Toremifene.	Approved, Investigational
Tramadol	The risk or severity of adverse effects can be increased when Tramadol is combined with Trazodone.	Approved, Investigational
Trans-2-Phenylcyclopropylamine	The risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Trazodone.	Experimental
Tranylcypromine	The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Trazodone.	Approved
Trastuzumab emtansine	The serum concentration of Trastuzumab emtansine can be decreased when it is combined with Trazodone.	Approved
Triazolam	The risk or severity of adverse effects can be increased when Trazodone is combined with Triazolam.	Approved
Trifluoperazine	The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Trazodone.	Approved
Triflupromazine	The risk or severity of adverse effects can be increased when Triflupromazine is combined with Trazodone.	Approved, Vet Approved
Trimipramine	The risk or severity of adverse effects can be increased when Trazodone is combined with Trimipramine.	Approved
Triprolidine	The risk or severity of adverse effects can be increased when Trazodone is combined with Triprolidine.	Approved
Tropisetron	Tropisetron may increase the serotonergic activities of Trazodone.	Approved, Investigational
Ulipristal	The serum concentration of Ulipristal can be decreased when it is combined with Trazodone.	Approved
Umeclidinium	The serum concentration of Umeclidinium can be decreased when it is combined with Trazodone.	Approved
Valproic Acid	The risk or severity of adverse effects can be increased when Valproic Acid is combined with Trazodone.	Approved, Investigational
Vandetanib	Trazodone may increase the QTc-prolonging activities of Vandetanib.	Approved
Vecuronium	The serum concentration of Vecuronium can be decreased when it is combined with Trazodone.	Approved
Vemurafenib	Trazodone may increase the QTc-prolonging activities of Vemurafenib.	Approved
Venetoclax	The serum concentration of Venetoclax can be decreased when it is combined with Trazodone.	Approved
Venlafaxine	Venlafaxine may increase the serotonergic activities of Trazodone.	Approved
Verapamil	The metabolism of Trazodone can be decreased when combined with Verapamil.	Approved
Vigabatrin	The risk or severity of adverse effects can be increased when Trazodone is combined with Vigabatrin.	Approved
Vilazodone	The risk or severity of adverse effects can be increased when Trazodone is combined with Vilazodone.	Approved
Vinblastine	The serum concentration of Vinblastine can be decreased when it is combined with Trazodone.	Approved
Vincristine	The serum concentration of Vincristine can be decreased when it is combined with Trazodone.	Approved, Investigational
Vismodegib	The serum concentration of Vismodegib can be decreased when it is combined with Trazodone.	Approved
Voriconazole	The metabolism of Trazodone can be decreased when combined with Voriconazole.	Approved, Investigational
Vortioxetine	The risk or severity of adverse effects can be increased when Trazodone is combined with Vortioxetine.	Approved
Warfarin	Trazodone may decrease the anticoagulant activities of Warfarin.	Approved
Yohimbine	The therapeutic efficacy of Trazodone can be decreased when used in combination with Yohimbine.	Approved, Vet Approved
Zaleplon	The risk or severity of adverse effects can be increased when Trazodone is combined with Zaleplon.	Approved, Illicit, Investigational
Ziconotide	The risk or severity of adverse effects can be increased when Trazodone is combined with Ziconotide.	Approved
Zidovudine	The serum concentration of Zidovudine can be decreased when it is combined with Trazodone.	Approved
Zimelidine	Zimelidine may increase the serotonergic activities of Trazodone.	Withdrawn
Ziprasidone	Trazodone may increase the QTc-prolonging activities of Ziprasidone.	Approved
Zolmitriptan	The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Trazodone.	Approved, Investigational
Zolpidem	Trazodone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.	Approved
Zonisamide	The risk or severity of adverse effects can be increased when Trazodone is combined with Zonisamide.	Approved, Investigational
Zopiclone	The risk or severity of adverse effects can be increased when Trazodone is combined with Zopiclone.	Approved
Zotepine	The risk or severity of adverse effects can be increased when Trazodone is combined with Zotepine.	Approved
Zuclopenthixol	Trazodone may increase the QTc-prolonging activities of Zuclopenthixol.	Approved, Investigational

Food Interactions

Avoid alcohol.
Food decreases the rate and extent of absorption.

References

Synthesis Reference

Not Available

General References

Marek GJ, McDougle CJ, Price LH, Seiden LS: A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology (Berl). 1992;109(1-2):2-11. [PubMed:1365657 ]
Jauch R, Kopitar Z, Prox A, Zimmer A: [Pharmacokinetics and metabolism of trazodone in man (author's transl)]. Arzneimittelforschung. 1976;26(11):2084-9. [PubMed:1037253 ]
Rotzinger S, Fang J, Baker GB: Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos. 1998 Jun;26(6):572-5. [PubMed:9616194 ]
Kalgutkar AS, Henne KR, Lame ME, Vaz AD, Collin C, Soglia JR, Zhao SX, Hop CE: Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4. Chem Biol Interact. 2005 Jun 30;155(1-2):10-20. Epub 2005 Apr 18. [PubMed:15978881 ]
Otani K, Yasui N, Kaneko S, Ishida M, Ohkubo T, Osanai T, Sugawara K, Fukushima Y: Trazodone treatment increases plasma prolactin concentrations in depressed patients. Int Clin Psychopharmacol. 1995 Jun;10(2):115-7. [PubMed:7673654 ]
Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, Gruber G, Mandl M, Strobl R, Gollner D, Prause W, Saletu B: Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Feb;26(2):249-60. [PubMed:11817501 ]
Fink HA, MacDonald R, Rutks IR, Wilt TJ: Trazodone for erectile dysfunction: a systematic review and meta-analysis. BJU Int. 2003 Sep;92(4):441-6. [PubMed:12930437 ]

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB14794
KEGG Compound	C07156
PubChem Compound	5533
PubChem Substance	46506648
ChemSpider	5332
BindingDB	50073444
ChEBI	9654
ChEMBL	CHEMBL621
Therapeutic Targets Database	DAP000104
PharmGKB	PA451744
IUPHAR	213
Guide to Pharmacology	213
Drug Product Database	1939
RxList	http://www.rxlist.com/cgi/generic/traz.htm
Drugs.com	http://www.drugs.com/trazodone.html
Wikipedia	Trazodone

ATC Codes

N06AX05 — Trazodone

AHFS Codes

28:16.04.24

PDB Entries

Not Available

FDA label

Download (151 KB)

MSDS

Download (73.7 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Suspended	Basic Science	Sleep Apnea, Obstructive; Post-Traumatic Stress Disorders	1
1	Completed	Treatment	Bioavailability / Healthy Volunteers / Pharmacokinetics	1
1	Completed	Treatment	Healthy Volunteers	3
1	Not Yet Recruiting	Treatment	Depressive State	1
1	Recruiting	Treatment	Sleep Apnea, Obstructive	1
1	Unknown Status	Treatment	Healthy Volunteers	1
2	Completed	Treatment	Alcoholism	1
2	Recruiting	Treatment	Painful Diabetic Neuropathy	1
2, 3	Completed	Treatment	Depressive State	1
3	Completed	Treatment	Alzheimer's Disease (AD)	1
3	Completed	Treatment	Alzheimer's Disease (AD) / Sleep / Sleep disorders and disturbances / Sleeplessness	1
3	Completed	Treatment	Major Depressive Disorder (MDD)	2
3	Completed	Treatment	Opiate Addiction / Poor Quality Sleep	1
3	Completed	Treatment	Sleep Disorder	1
3	Recruiting	Treatment	Anxiety Disorder / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders	1
4	Active Not Recruiting	Treatment	Insomnia Comorbid to Psychiatric Disorder / Primary Insomnia	1
4	Completed	Treatment	Fibromyalgia	1
4	Completed	Treatment	Schizophrenic Disorders	1
4	Recruiting	Other	Sleep Apnea Syndrome / Spinal Cord Injuries (SCI)	1
4	Terminated	Treatment	Acute Agitation / Delirium	1
4	Unknown Status	Treatment	Major Depressive Disorder (MDD)	1
4	Unknown Status	Treatment	Mental Health Disorder / Sleeplessness / Substance Use Disorder (SUD)	1
Not Available	Active Not Recruiting	Treatment	Spinal Stenosis of Lumbar Region	1
Not Available	Completed	Basic Science	Sleep Apnea, Obstructive	1
Not Available	Completed	Treatment	Sexual Dysfunctions	1
Not Available	Recruiting	Basic Science	Sleep Disordered Breathing (SDB) / Spinal Cord Injuries (SCI)	1
Not Available	Recruiting	Treatment	Alcohol-Related Disorders / Brain Injury / Chronic Diseases / Depressive State / Mild Cognitive Impairment (MCI) / Pain / Posttraumatic Stress Disorders / Quality of Life / Substance-Related Disorders / Suicidal Ideation / Wounds and Injuries	1
Not Available	Recruiting	Treatment	Antidepressant Drug Adverse Reaction / Depressive State	1
Not Available	Recruiting	Treatment	Sleeplessness	1
Not Available	Unknown Status	Treatment	Treatment Resistant Depression (TRD)	1

Pharmacoeconomics

Manufacturers

Labopharm inc
Apothecon inc div bristol myers squibb
Alvogen inc
American therapeutics inc
Apotex inc
Matrix laboratories ltd
Mutual pharmaceutical co inc
Mylan pharmaceuticals inc
Pliva inc
Quantum pharmics ltd
Sandoz inc
Teva pharmaceuticals usa inc
Usl pharma inc
Vintage pharmaceuticals llc
Watson laboratories inc

Packagers

Advanced Pharmaceutical Services Inc.
Amerisource Health Services Corp.
Apotex Inc.
Apothecon
AQ Pharmaceuticals Inc.
A-S Medication Solutions LLC
Barr Pharmaceuticals
Bristol-Myers Squibb Co.
Bryant Ranch Prepack
Cardinal Health
Caremark LLC
Corepharma LLC
Coupler Enterprises Inc.
DHHS Program Support Center Supply Service Center
Direct Dispensing Inc.
DispenseXpress Inc.
Dispensing Solutions
Diversified Healthcare Services Inc.
Golden State Medical Supply Inc.
Goldline Laboratories Inc.
H.J. Harkins Co. Inc.
Heartland Repack Services LLC
Innoviant Pharmacy Inc.
Kaiser Foundation Hospital
Keltman Pharmaceuticals Inc.
Labopharm Inc.
Lake Erie Medical and Surgical Supply
Letco Medical Inc.
Liberty Pharmaceuticals
Major Pharmaceuticals
Mckesson Corp.
Medisca Inc.
Medvantx Inc.
Murfreesboro Pharmaceutical Nursing Supply
Mutual Pharmaceutical Co.
Mylan
Neighborcare Repackaging Inc.
Novopharm Ltd.
Nucare Pharmaceuticals Inc.
Palmetto Pharmaceuticals Inc.
PCA LLC
PD-Rx Pharmaceuticals Inc.
Pharma Pac LLC
Pharmaceutical Utilization Management Program VA Inc.
Pharmacy Service Center
Physicians Total Care Inc.
Pliva Inc.
Preferred Pharmaceuticals Inc.
Prepackage Specialists
Prepak Systems Inc.
Prescription Dispensing Service Inc.
Qualitest
Rebel Distributors Corp.
Remedy Repack
Resource Optimization and Innovation LLC
Sandhills Packaging Inc.
Shanghai World Prospect Industrial Co. Ltd.
Southwood Pharmaceuticals
St Mary's Medical Park Pharmacy
Stat Rx Usa
Teva Pharmaceutical Industries Ltd.
United Research Laboratories Inc.
Va Cmop Dallas
Vangard Labs Inc.

Dosage forms

Form	Route	Strength
Tablet	Oral	150 mg
Tablet	Oral	50 mg
Tablet	Oral	300 mg
Tablet, extended release	Oral	150 mg
Tablet, extended release	Oral	150 mg/1
Tablet, extended release	Oral	300 mg
Tablet, extended release	Oral	300 mg/1
Tablet	Oral	100 mg
Tablet	Oral	75 mg
Kit
Tablet	Oral	100 mg/1
Tablet	Oral	150 mg/1
Tablet	Oral	300 mg/1
Tablet	Oral	50 mg/1
Tablet, film coated	Oral	100 mg/1
Tablet, film coated	Oral	150 mg/1
Tablet, film coated	Oral	50 mg/1
Tablet	Oral	68.25 mg

Prices

Unit description	Cost	Unit
Trazodone hcl powder	8.26USD	g
Desyrel 300 mg tablet	6.03USD	tablet
TraZODone HCl 300 mg tablet	5.65USD	tablet
Trazodone 300 mg tablet	5.44USD	tablet
Desyrel 100 mg tablet	4.6USD	tablet
Desyrel 150 mg tablet	3.39USD	tablet
TraZODone HCl 150 mg tablet	1.53USD	tablet
Trazodone 150 mg tablet	1.47USD	tablet
Desyrel 50 mg tablet	1.33USD	tablet
TraZODone HCl 100 mg tablet	0.76USD	tablet
Trazodone 100 mg tablet	0.73USD	tablet
Apo-Trazodone D 150 mg Tablet	0.61USD	tablet
Desyrel Dividose 150 mg Tablet	0.61USD	tablet
Novo-Trazodone 150 mg Tablet	0.61USD	tablet
Nu-Trazodone-D 150 mg Tablet	0.61USD	tablet
Ratio-Trazodone 150 mg Tablet	0.61USD	tablet
TraZODone HCl 50 mg tablet	0.59USD	tablet
Trazodone 50 mg tablet	0.57USD	tablet
Nu-Trazodone 100 mg Tablet	0.41USD	tablet
Pms-Trazodone 100 mg Tablet	0.41USD	tablet
Ratio-Trazodone 100 mg Tablet	0.41USD	tablet
Apo-Trazodone 100 mg Tablet	0.41USD	tablet
Desyrel 100 mg Tablet	0.41USD	tablet
Mylan-Trazodone 100 mg Tablet	0.41USD	tablet
Novo-Trazodone 100 mg Tablet	0.41USD	tablet
Pms-Trazodone 75 mg Tablet	0.34USD	tablet
Apo-Trazodone 50 mg Tablet	0.23USD	tablet
Mylan-Trazodone 50 mg Tablet	0.23USD	tablet
Novo-Trazodone 50 mg Tablet	0.23USD	tablet
Nu-Trazodone 50 mg Tablet	0.23USD	tablet
Pms-Trazodone 50 mg Tablet	0.23USD	tablet
Ratio-Trazodone 50 mg Tablet	0.23USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US6607748	No	2000-06-29	2020-06-29	US
US7829120	No	2007-03-27	2027-03-27	US
US8133893	No	2009-03-13	2029-03-13	US

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	87 °C	PhysProp
water solubility	Sparigly soluble	Not Available
logP	2.9	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.29 mg/mL	ALOGPS
logP	2.68	ALOGPS
logP	3.13	ChemAxon
logS	-3.1	ALOGPS
pKa (Strongest Basic)	7.09	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	4	ChemAxon
Hydrogen Donor Count	0	ChemAxon
Polar Surface Area	42.39 Å²	ChemAxon
Rotatable Bond Count	5	ChemAxon
Refractivity	105.88 m³·mol^-1	ChemAxon
Polarizability	40.12 Å³	ChemAxon
Number of Rings	4	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	1.0
Blood Brain Barrier	+	0.9829
Caco-2 permeable	-	0.6166
P-glycoprotein substrate	Substrate	0.547
P-glycoprotein inhibitor I	Inhibitor	0.8634
P-glycoprotein inhibitor II	Inhibitor	0.8889
Renal organic cation transporter	Inhibitor	0.6479
CYP450 2C9 substrate	Non-substrate	0.7897
CYP450 2D6 substrate	Substrate	0.8919
CYP450 3A4 substrate	Substrate	0.7408
CYP450 1A2 substrate	Non-inhibitor	0.9045
CYP450 2C9 inhibitor	Non-inhibitor	0.9071
CYP450 2D6 inhibitor	Non-inhibitor	0.9231
CYP450 2C19 inhibitor	Non-inhibitor	0.9026
CYP450 3A4 inhibitor	Non-inhibitor	0.6613
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.83
Ames test	Non AMES toxic	0.5133
Carcinogenicity	Non-carcinogens	0.8545
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	2.7007 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Strong inhibitor	0.8994
hERG inhibition (predictor II)	Inhibitor	0.7503

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
LC-MS/MS	LC-MS/MS Spectrum - , positive	splash10-00di-0609000000-cee74b5bf3182c2aa324	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available
MS	Mass Spectrum (Electron Ionization)	splash10-0a4i-7980000000-5d2bde624fdd9a946993	View in MoNA

Taxonomy

Description

This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Diazinanes

Sub Class

Piperazines

Direct Parent

Phenylpiperazines

Alternative Parents

N-arylpiperazines / Aryl 1,2,4-triazolones / Triazolopyridines / Aniline and substituted anilines / Dialkylarylamines / Pyridinones / Chlorobenzenes / N-alkylpiperazines / Aryl chlorides / Heteroaromatic compounds

Substituents

Phenylpiperazine / N-arylpiperazine / Aryl 1,2,4-triazol-3-one / Triazolopyridine / Tertiary aliphatic/aromatic amine / Aniline or substituted anilines / Dialkylarylamine / Pyridinone / Chlorobenzene / N-alkylpiperazine

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

N-arylpiperazine, monochlorobenzenes, N-alkylpiperazine, triazolopyridine (CHEBI:9654 )

Targets

Details

1. 5-hydroxytryptamine receptor 2A

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: antagonist

General Function:: Virus receptor activity
Specific Function:: G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:: HTR2A
Uniprot ID:: P28223
Molecular Weight:: 52602.58 Da

References

Pazzagli M, Giovannini MG, Pepeu G: Trazodone increases extracellular serotonin levels in the frontal cortex of rats. Eur J Pharmacol. 1999 Nov 3;383(3):249-57. [PubMed:10594316 ]
Marcoli M, Rosu C, Bonfanti A, Raiteri M, Maura G: Inhibitory presynaptic 5-hydroxytryptamine(2A) receptors regulate evoked glutamate release from rat cerebellar mossy fibers. J Pharmacol Exp Ther. 2001 Dec;299(3):1106-11. [PubMed:11714900 ]
Marek GJ, McDougle CJ, Price LH, Seiden LS: A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology (Berl). 1992;109(1-2):2-11. [PubMed:1365657 ]
Luparini MR, Garrone B, Pazzagli M, Pinza M, Pepeu G: A cortical GABA-5HT interaction in the mechanism of action of the antidepressant trazodone. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Nov;28(7):1117-27. [PubMed:15610924 ]
Conn PJ, Sanders-Bush E: Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. J Pharmacol Exp Ther. 1987 Aug;242(2):552-7. [PubMed:3039120 ]
Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]

Details

2. 5-hydroxytryptamine receptor 2C

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: agonist

General Function:: Serotonin receptor activity
Specific Function:: G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:: HTR2C
Uniprot ID:: P28335
Molecular Weight:: 51820.705 Da

References

Fiorella D, Rabin RA, Winter JC: The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of m-chlorophenylpiperazine. Psychopharmacology (Berl). 1995 May;119(2):222-30. [PubMed:7659770 ]
Conn PJ, Sanders-Bush E: Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. J Pharmacol Exp Ther. 1987 Aug;242(2):552-7. [PubMed:3039120 ]

Details

3. Sodium-dependent serotonin transporter

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Serotonin:sodium symporter activity
Specific Function:: Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:: SLC6A4
Uniprot ID:: P31645
Molecular Weight:: 70324.165 Da

References

Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]

Details

4. 5-hydroxytryptamine receptor 1A

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: partial agonist

General Function:: Serotonin receptor activity
Specific Function:: G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:: HTR1A
Uniprot ID:: P08908
Molecular Weight:: 46106.335 Da

References

Odagaki Y, Toyoshima R, Yamauchi T: Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding. J Psychopharmacol. 2005 May;19(3):235-41. [PubMed:15888508 ]
Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Subhash MN, Srinivas BN, Vinod KY: Alterations in 5-HT(1A) receptors and adenylyl cyclase response by trazodone in regions of rat brain. Life Sci. 2002 Aug 16;71(13):1559-67. [PubMed:12127910 ]

Details

5. Histamine H1 receptor

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: antagonist

General Function:: Histamine receptor activity
Specific Function:: In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:: HRH1
Uniprot ID:: P35367
Molecular Weight:: 55783.61 Da

References

Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881 ]
Noguchi S, Inukai T, Kuno T, Tanaka C: The suppression of olfactory bulbectomy-induced muricide by antidepressants and antihistamines via histamine H1 receptor blocking. Physiol Behav. 1992 Jun;51(6):1123-7. [PubMed:1353628 ]

Details

6. Alpha-1A adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: no
Actions: antagonist

General Function:: Protein heterodimerization activity
Specific Function:: This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:: ADRA1A
Uniprot ID:: P35348
Molecular Weight:: 51486.005 Da

References

Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]

Details

7. Alpha-2A adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: no
Actions: antagonist

General Function:: Thioesterase binding
Specific Function:: Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:: ADRA2A
Uniprot ID:: P08913
Molecular Weight:: 48956.275 Da

References

Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]

Enzymes

Details

1. Cytochrome P450 3A4

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Vitamin d3 25-hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:: CYP3A4
Uniprot ID:: P08684
Molecular Weight:: 57342.67 Da

References

Rotzinger S, Fang J, Baker GB: Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos. 1998 Jun;26(6):572-5. [PubMed:9616194 ]
Kalgutkar AS, Henne KR, Lame ME, Vaz AD, Collin C, Soglia JR, Zhao SX, Hop CE: Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4. Chem Biol Interact. 2005 Jun 30;155(1-2):10-20. Epub 2005 Apr 18. [PubMed:15978881 ]
Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Details

2. Cytochrome P450 3A5

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Oxygen binding
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:: CYP3A5
Uniprot ID:: P20815
Molecular Weight:: 57108.065 Da

References

Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Details

3. Cytochrome P450 3A7

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Oxygen binding
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:: CYP3A7
Uniprot ID:: P24462
Molecular Weight:: 57525.03 Da

References

Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Details

4. Cytochrome P450 2D6

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Steroid hydroxylase activity
Specific Function:: Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:: CYP2D6
Uniprot ID:: P10635
Molecular Weight:: 55768.94 Da

References

Wen B, Ma L, Rodrigues AD, Zhu M: Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine. Drug Metab Dispos. 2008 May;36(5):841-50. doi: 10.1124/dmd.107.019471. Epub 2008 Jan 31. [PubMed:18238857 ]
Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Details

1. Alpha-1-acid glycoprotein 1

Kind: Protein
Organism: Human
Pharmacological action: no

General Function:: Not Available
Specific Function:: Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:: ORM1
Uniprot ID:: P02763
Molecular Weight:: 23511.38 Da

References

Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173 ]

Transporters

Details

1. Multidrug resistance protein 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inducer

General Function:: Xenobiotic-transporting atpase activity
Specific Function:: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:: ABCB1
Uniprot ID:: P08183
Molecular Weight:: 141477.255 Da

References

Stormer E, von Moltke LL, Perloff MD, Greenblatt DJ: P-glycoprotein interactions of nefazodone and trazodone in cell culture. J Clin Pharmacol. 2001 Jul;41(7):708-14. [PubMed:11452702 ]

Drug created on June 13, 2005 07:24 / Updated on July 11, 2017 01:58

Get DrugBank to go!

Structure for DB00656 (Trazodone)

Targets

References

References

References

References

References

References

References

Enzymes

References

References

References

References

Carriers

References

Transporters

References